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INTRODUCTION 
Every Traditional System of medicine was directly connected with our culture 
and tradition. Evolution of human society, Tamil civilization peoples obviously learn 
the cause of human sufferings not only disease, ageing, life problems it absolutely 
about the purpose of human life. Some peoples understood the purpose of human life 
and they lives accordingly to achieve enlightenment called Siddhars.  
Siddhars, men of highly cultured intellectuals and spiritual faculties combined 
with supernatural powers so called sages, saints. They wrote their experiences in palm 
manuscripts to share knowledge to human society. They strongly believed that 
healthful body is essential to attain the immortal life. 
To achieve the goal of human life every human needs healthy body. So they 
discover medicines to cure human sufferings. This medicine was collectively called as 
Siddha system medicine. This system of medicine imitate with our mother nature.  
The Siddhar, Thirumoolar  has written in his song  
“உடம்பா யறி஬ில் உ஬ி஭ாயறிலர் 
திடம்பட ம஫ய்ஞனம் சே஭வும் ஫ாட்டார் 
உடம்பப லரர்க்கும் உபா஬ம் அமிந்சத 
உடம்பப லரர்சதன் உ஬ிர் லரர்சதசன”  
                                                       - திருமூயர்
 (1) 
Accordingly the physical and mental wellbeing is more important to lead a 
healthy life. Nutritious lifestyle comprises all day to day activities and food habits.  
There are five basic primordial elements in nature viz. earth, water, fire, wind, 
ether and everything is made up of these elements. The food we intake consists of six 
taste viz. sweet, sour, salt, bitter, acrid and astringent. These six tastes are formed by 
the selective combination of those five primordial elements.  
Moreover there are three humours viz., Vatham, Pitham and Kabam, which is 
responsible for the physical and mental quality and also maintain the healthy body. 
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Any changes in the food habits and lifestyle brings imbalance of vatham, pitham and 
kabham which is the cause for the disease. Thus there is an interconnection between 
the five primordial elements, six tastes and three humours which are the basic 
fundamental of Siddha System. 
The Siddha treatment peruses at the proper balance and equilibrium of the 
three humours through proper diet and perfect lifestyle.  
In recent years the Siddha system has its dawn among worldwide for its 
natural inheritance, holistic approach, healthy lifestyle and preventive treatment. 
Siddhar Therayar, one of the pioneers of the Siddha medical system, he 
explained excessive urination or decreased urination comes under by Neerinai 
perukkal noi and Nerinai arukkal noi.  So Madhumegam is classified under “Neerinai 
perrukkal noi”(2). 
            Yugi Muni describes 20 types of Meganoigal, Madhumegam is one among 
them. 
The word Madhumegam is very similar and closely resembles with the 
chronic metabolic disorder called Diabetes Mellitus-Type II in Modern medicine. 
This is mainly because of the Etymology that, 
           “Mellitus” means sweetness which means “Madhu”. 
           “Diabetes” means “Passing  like a Fountain”  
 
In the world Non communicable diseases silently attacks more people every 
day. In this diabetes mellitus is the most common one. 
            Diabetes mellitus is a group of metabolic disorder in which a person has high 
blood sugar, either because the pancreas does not produce enough Insulin, or because 
cells do not respond to the Insulin that is produced. This high blood sugar produces 
the classical symptoms of Polyuria (frequent urination), Polydipsia (increased thirst) 
and Polyphagia (increased hunger) 
(3)
. 
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Diabetes is fast gaining the status of a potential epidemic in India with more 
than 62 million diabetic individuals. The study conducted by ICMR revealed that a 
lower population is affected in Tamilnadu is 4.8 million 
(4)
. 
WHO projects that diabetes will be the seventh leading cause of death in 2030 
(who fact sheet November 2017) 
(5)
. 
The sudden spurt in life style modification and vast urbanization has made 
India the Diabetic capital of the World.  
Seeking the solution for this, our attention heads towards natural ways and 
medicines especially Siddha system of medicine. Siddha medicine is an unique one as 
it is not only a curative but also preventive and to achieve the salubrious body and 
mind. 
Siddha medicine plays an effective role in treating Diabetes mellitus. At 
present most of the anti-diabetic medicines used for a long period, produce 
hypoglycemia and may bring many undesirable side effects too.  So there is a need for 
the medicine which could be more potent and cause lower side effects to the mankind 
continues. So I consider my medicine “Perungaya Chooranam” as a unique 
preparation formulated by Siddhars against Diabetes mellitus. 
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AIM AND OBJECTIVES 
 
AIM: 
The Aim of this study is to evaluate the Clinical Efficacy and Safety of Siddha 
Medicine “Perungaya chooranam” in the management of Madhumegam. 
OBJECTIVES: 
1) To review the Siddha literary evidences dealing with Aetiology, 
Classifications, Signs & Symptoms, Diagnosis, Diet and Prognosis of 
Madhumegam in Siddha system of Medicine. 
2) To study Madhumegam in various literatures in comparison with Diabetes 
Mellitus -Type II. 
3) To understand the incidence of the disease with reference to Age, Sex, 
Thinaigal, Paruvakaalam, Socio Economic conditions, Diet and Family 
history. 
4) To explore the unique diagnostic methods mentioned by Siddhars such as 
Envagai thervu, Mukkuttram, Udal thathukkal with specific reference by 
Naadi, Neerkuri and Neikuri. 
5) To implement Siddha and utilize Modern parameters to diagnose and to 
confirm the severity & progress of the disease. 
6) To evaluate the Bio-chemical analysis of the trial medicine. 
7) To assess the Acute and Sub- Acute toxicity of the trial medicine. 
8) To study the Anti- Diabetic activity of the trial medicine. 
9) To evaluate the Clinical study of the trial medicine. 
10) To analyze the Biostatic analysis of the trial medicine. 
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                                        SIDDHA ASPECT 
   
 “஡க்க ஡ா஧஠ி ஥ாணிடத்த஡ார்கள் 
               தக்க஥ாசனம் தத்஡ிய௃஬ககயுத஥ 
  ஢க்க ஢ா஦கன் ஢ா஦கிக்தக சசால் 
                                        ஥ிக்க ஢ந்஡ி ஬ிபம்தி ஬ி஡ித்஡த஡” 
- த஡க஧஦ர் ஬ாகடம் 
(6) 
  
 According to Therayar Vagadam, “The universe consist of two essential 
existences that is, matter and energy which Siddhar’s referred to as Shiva and Sakthi”. 
Shiva explained Megarogam to Sakthi. Here Nandhi explains its symptoms to the 
world for the benefit of the human kind. 
 
                             “ஆ஥ப்தா ஥ணி஡ர் சசய்஡ கன்஥த்஡ாதன 
                                        அ஧க஧ா த஥கச஥ன்ந ஧ாசா஬ாதன” 
                        - அகத்஡ி஦ர் 
(7) 
 
This clearly indicates that the existence of this disease is as old as human race. 
 
 “஥ிகித௅ம் குகந஦ித௅ம் த஢ாய்சசய்யும் த௄தனார் 
               ஬பி ப௃஡னா எண்஠ி஦ ப௄ன்று”  
     - ஡ிய௃க்குநள் 
(8)
    
 All the diseases are due to alteration of three vital humours and seven physical 
Constituents.The factors, which affect this equilibrium of vital humours are, 
Unavu Marupadugal (Altered diet habit) 
Kala marupadugal (Seasonal variations) 
Thega vanmai (Depending upon immunological status) 
According to Siddhars, the imbalance of tridosha causes totally 4448 diseases 
to human beings. Among them, Megarogam is considered to be the emperor of 
diseases.  
Madhumegam has its description in various literatures like Yugi Vaithya 
Chindamani, Agasthiyar Gunavagadam. 
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            Earlier, diseases were classified only according to Mukkutram. Yugi Munivar 
classified the diseases according to cause, signs and symptoms and also explained 
about the prognosis, treatment and diet, which is now followed by the modern world. 
Madhumegam comes under Neerinai perukkal Noi, mentioned in Therayar Maha 
Karisal.      
“஢ீாிய௃஬ிகணக் கு஠த்க஡ ஢ீ஦நி ஬ிாித்துச் சசால்஬ாம் 
஢ீாிகணப் சதய௃க்கசனான்று ஢ீாிகண ஦ய௃க்க சனான்று”  
                                           - த஡க஧஦ர் ஥கா காிசல் 
(9) 
VERUPEYARGAL (SYNONYMS) 
               Neerizhivu, Enippuneer, Vegumoothiram, Thithippuneer, Miguneer 
(10)
  
               Neerizhivu                                 - Excess of urination. 
               Enippu Neer/ Thithippu neer     - The urine is sweet in taste. 
               Vegu Moothiram                       - Frequency and large quantity of urine          
                                                                    passed 
               Pramegam                                  - Sanskrit name for Madhumegam 
  
IYAL (DEFINITION) 
       Madhumegam is a clinical condition characterized by frequent passage of urine 
more than the normal resulting in deterioration and diminution of the seven thathus. 
இணிப்தாண இணிப்தல்ன ஈ ஬ந்஡ாடும் 
             ஑ய௃துபி஬ாய் ஬ிட்டார்ககப் தி஠ி஦ாய் த஡ான்றும்  
                                                             - குய௃ ஢ாடி 
(11) 
The above quote describes that ant and flies are attracted to the site of voided 
urine and when the urine is heated, it gives honey odour. 
 “஡ண்க஥஦ாய்ச் சனந்஡ாத௅ம் தசுப்பு ஥ஞ்சள் 
  ஡ாணிநங்கும் பீசப௃ங்தகா சப௃ங்க டுக்கும் 
 அண்க஥஦ா ஦டிக்கடிக்கு ஢ீாிநங்கு 
  ஥டிக்கடிக்கு அக஧஢ா஫ி ஡ணிதன காணும் 
 ச஬ண்க஥஦ாண ஦டி஦஡ணிற் நான்திடிக்கும் 
  ஥ிக்காண சடம்ச஬ளுத்து த஥ணிகன்றும் 
 தண்க஥஦ாய்ப் தஞ்ச஬ாண் ட஡ணிற் சகால்லும் 
                                                தகிர்கின்ந ஥துத஥கப் தாங்கு ஡ாதண”  
                                 - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(12)
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      These lines quote frequent micturition, more than the normal with large quantity 
resulting in detoriation of gradual dimnision of seven udal thathukkal. 
   “஢ீாிகணப் சதய௃க்கசனன்று ஢ீாி஫ி ஬ினக்க஠ங்தகள் 
஢ீன஬ாாி஡ி ததாற் குக்கி ஢ீட்டிக்கு ப௃க஧ ஡ள்பாகும் 
஢ீ஬ி கூடாது கக கால் ஢ீன஥ா ஬ிகண த஢஧ாகும் 
஢ீள் சசாணாவு஧ணின் ப௄ச்சு ஢ீச஥ா ப௃஦ங்கக்காட்டும் 
                      - த஡க஧஦ர் ஥கா காிசல் 
(13) 
Abdomen distends like sea, slurring of speech, peripheral neuritis, lassitude, 
dyspnoea are the symptoms of Madhumegam. 
As per Athma Rakshamirrtham, body becomes weak, weight loss, dryness of 
skin and tongue, excessive thirst, tiredness, excess sleep indicate the presence of 
Megaroham.  
 
NOI VARUM VAZHI-AETIOLOGY: 
“த஥கச஥த௅ம் ஢ீாி஫ிவு ஬ி஡த்க஡ 
஬ிபம்புகிதநன் ப௃ன்சசய்஡ கர் ஥ந்஡ன்ணால் 
஡ாகப௃டன் ஥துத஡ார்த்஡ங்கள் ஢ன்நாய்த் 
஡ான்புசித்஡ னாலுஞ்சிற்நிணத்஡ின் ஥ங்கக 
ததாக஥஡ி காித்஡னா லுட்டின்ந்஡ான் 
ததா஡த஬ ஥ிஞ்சு஡னால் ஡஦ிர்த஥ார் ச஢ய்தால் 
ஏக஥ாய்ப் புசித்஡னாற் சகாழுத்஡ வூகண 
ச஦ன்று ப௃ண்஠ லு஬ந்஢ீக஧க் குடித்஡னாதன 
ஆகசயுடன் சிறு஬ழு஡னங்காய் ஡ன்கண 
஦஡ிக஥ா யுண்த஡ால் ஢கட஦கனச்சல் 
ததா஡த஬ ஦ிய௃த்஡லி஧ா கண்஬ி஫ித்஡ல் 
த஡சச஥ங்கு ஡ிாி஡னா ஥ிக஬கபாதன 
                                சி஧ந்஡ணிற்சூ ட்஡ிகங் சகாண்டுடதண ஧த்஡ம் 
தசா஭ித஡ ஦஡ிக஥ாய் த஥கந்த஡ான்நித் 
ச஡ால்கன சசய்யும் ஢ீாி஫ிவும் இய௃த஡ாத஥”         
                                 - ச஧ததந்஡ி஧ த஥க஢ி஬ா஧஠ ததா஡ிணி ஏன்த௅ம் ஢ிாி஫ிவுத஢ாய் ஥ய௃த்து஬ம் 
(14) 
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DIET HABITS : 
 
                         “தகாக஡஦ர் கன஬ி ததாக஡ 
சகாழுத்஡஥ீ ணீகநச்சி ததாக஡ 
தாது஬ாய் ச஢ய்யுண் தாலும் 
தாிவுட ண்பீ ஧ாகில் 
தசா஡தாண் டுய௃஬ ஥ிக்க 
சுக்கின தி஧த஥ கந்஡ான் 
஑து஢ீ ாி஫ிவு தச஧ 
உண்சடண ஬நிந்து சகாள்தப” 
                                  - அகத்஡ி஦ர் 1200 
(15) 
 
“உற்த஬ிக்கும் தால்ச஢ய்஦ா லிகநச்சி கள்பால் 
உாிகச஦ாய் ஥ீன்நன்ணா ல்஬ய௃஬ி ய௃த்஡ 
஥ற்த஬ிக்கும் த஡ார்த்஡த்஡ால் ஥து஧ ஬ஸ்஡ால் 
஥ந்஡ங்கள் ஡ணிற்சதாசித்஡ல் த஬காப் தண்டம் 
குற்த஬ிக்குங் குபிந்஡஬ன்ண ஥ங்கக தகாஷ்டி 
குநித்஡ ஢ித்஡ிக஧஡஬ிர் ஡னக்கிணி ஥ந்஡ம் 
஡ற்த஬ிக்குஞ் சாீ஧ந்஡ான் ஥ிகப்தய௃க்கல் 
சஞ்சனந்஡ான் த஦ன்தடு஡ல் ஡ாிக்கும் த஢ாச஦” 
                                    - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(16) 
Excessive intake of food, rich in carbohydrate and fat, red meat, sweet food, 
Raw food and sleeplessness induces mathumegam, which was quoted by Agathiyar 
and Yugi Munivar. 
SEXUAL INDULGENCE: 
“கன்ணி ஥஦க்கத்஡ால் கண்டிடு த஥கத஥” 
                - ஢ாடி த௄ல் 
(17) 
 
“கி஧ந்஡ிப் புண்஠ி஧஠ த஥கக் 
கீசக சணன்த௅ந் துன் ஥ார்க்கன் 
அய௃ந்஡஡ி ச஦ன்த௅ம் தாஞ்சாலி 
஦ன்கணக஦க் கண்ணுற்நாதண” 
                            - த஡க஧஦ர் ஥ய௃த்து஬ தா஧஡ம் 
(18) 
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According to Thirumoolar and Therayar, excessive indulgence in sex causes 
Megaroham. 
 
OBESITY :   
                     
“஡ற்த஬ிக்குஞ் சாீ஧ந்஡ான் ஥ிகப்த ய௃க்கல் 
சஞ்சனந்஡ான் த஦ன்தடு஡ல் ஡ாிக்கும் த஢ாத஦” 
- யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(19)
                                         
Obesity is one of the main cause of Madhumegam. 
 
PSYCHOSOMATIC CAUSE:                              
“இ஦ம்தத஬ ஆறுகு஠ம் தின்ணஞ் சசய்஡ல் 
ஏற்ந஥ாய் ஥ாற்நான்சதண் சங்கம் சசய்஡ல் 
  த஦ம்தத஬ தானகர்களுக் சகாபித்து ஡ின்ணல் 
  த஫க஥ சனம்ததாந஬ ஫ி஡கண ஡டுத்஡ல் 
  அ஦ம்தத஬ ஆன஦த்஡ிற் சனம்஬ிட்தடார்க்கும் 
  ஆ஡ி஦ாம் த஬஡த்க஡த் தூ஭ித் த஡ார்க்கும் 
  து஦ம்தத஬ சூாி஦கண ஬஠ங்கா ஡ார்க்கும் 
  சுய௃க்காக த஥கம்஬ந்஡துற் த஬ிக்குந் ஡ாதண” 
      - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(22) 
                                                  
        According to Yugi Vaidya Chinthamani, Megaroham may occur due to not 
giving proper respect to Guru, Father, Mother, Vedas and God Suriyan. 
 
HEREDITARY: 
“ப௃கநதகட்கின் ஑ன்தது ப௃஦ற்சி஦ால் ஬ந்஡து 
஡கந தகட்கிந கய௃ப்தத்஡ிற் று஬ங்கி஦ த஥கங்கள் 
பூத்஡ சகாங்கக஦ாள் ஢ா஦கன் த஥ாகத்஡ால் 
஥கந ததாற்றுங் கய௃ப்தத்஡ில் ஬பர்ந்஡து த஥கத஥” 
                                  - அகத்஡ி஦ர் க஬த்஡ி஦ கா஬ி஦ம் 
(21) 
 
Thirumoolar have noted in his literatures that Hereditary is one among the 
causes of the disease Madhumegam. At present, researches have also found that 
genetic factors play an important role in Madhumegam. 
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EXCESS STIMULATION OF MOOLATHARAM: 
“சாி஦ாணத஥கத்஡ா னதாண ஬ாயு 
஡ான் புககக்கு த஥தனநிக் கதானச் சூடாம் 
  சதாி஡ாண த஥கத்஡ா னத்஡ி ச஬ந்து 
   ததா஥ப்தா ஡கசச஬ந்து ஧த்஡ம் ஬ற்நிப் 
  தாி஬ாகித் ஡ச ஬ாய்஬ால் ஥ந்஡ம் சகாண்டு 
   சதய௃ந்஡ீணி ஥னதந்஡ம் உ஡ாண ஬ாயு 
  ஬ிாி஬ாகித் த஡கச஥ல்னாம் ஬ிட ஢ீ஧ாதன 
   ச஥ய்஦஫ிந்஡ த஡கச஥ன்ந ஡ிய௃த஡ாச்தச” 
                                               - த஢ாய் ஢ாடல் 
(22)
  
 Among the six Atharams, the Moolatharam is situated in between rectum and 
genitals, just end of sacral plexus. 
             In the Madhumegam disease, impaired Abana vayu (excretory junction) 
inactivate the moola agini during that time excess intake of food causes inactivation 
of dhasavayu which create excessive appetite (Polyphagia) and constipation. Udanan 
is also affected. These changes in turn cause the derangement of seven udal thathukal. 
 
 DEEDS: 
“஡ாதண பூய௃஬ ஬ி஡ி஦ிணால் சாய௃ம் தி஠ிக சபல்னாம் 
஥ாதணர் ஬ி஫ி஦ாள் த஬ட்கக஦ிணால் ஬ய௃ந்தும் தின்த௅ம் தசி஦ால் 
஡ாதண சதாறுத்து உண்கக஦ிணால் ஡ாகந்஡ன்ணால் ஥ிகச்தசார்ந்து 
஡ாதண க஥னம் புண்஠ாகி சசய்யும் தி஧த஥ச் சச஦ல்஡ாதண” 
                                    - த஡க஧஦ர் ஥ய௃த்து஬ தா஧஡ம் 
(23) 
From the above poem, the diseases also occur as a result of bad deeds 
committed in previous or this birth. 
 
MURKURIGUNAM (PREMONITORY SYMPTOMS): 
                  Premonitory symptoms of Madhumegam are polyuria, polyphagia, 
polydipsia. Madhumegam exhibits the following premonitory symptoms from its 
initial stage of development itself. The patient experiences voracious hunger, thirst, 
perspiration, exhaustion and giddiness. The excessive intake of water to quench thirst 
is excreted as excessive quantity of urine (poly uria). In spite of abnormal 
consumption of food, stamina continues to decrease. 
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PODHU KURIGUNANGAL (GENERAL SIGNS & SYMPTOMS) 
“கூநாண த஥க஥து ஬ிய௃த துக்குங் 
கு஠ந்஡கணச் சி஬ன்சசால்னத் த஡஬ி தகட்கத் 
஡ாநாண ஡ாகச஥ாடு தசாக த஥க்கந் 
஡ாி஦ா஥ல் ஢ீ஧஫ி஡ லிய௃஥ல் ப௄ச்சு 
ஆநாண அய௃சிசர்த்஡ி சித்஡ப் தி஧க஥ 
஦டிக்கடித்வ் ஡ண்஠ீர்஡ா ணன்ணங் தகட்டல் 
ஈநாண ஬ிடுப்புக்குக் கடுப்பு கா஠ல் 
எலும்பு஫ற்ந ன஫ற்நதனா சடாிவுண் டாத஥” 
 
“எாித஬ாடு சாீ஧ச஥னா ஥கநதட் டாற்ததா 
சன஫ிலுடம்பு த஢ா஡ல்஢ித் ஡ிக஧஦ில் னாக஥ 
                          ஬ாிச஬ாடு ஬ாயுக஥த் ஡வும்த ாித்஡ல்  
஥ணதுசஞ் சனப்தடு஡ல் காற்று த஬ண்டல் 
ச஥ாித஬ாடு த஥ல் ப௄ச்சு ஥ிகவுண் டா஡ல்  
஬ிக்கசனாடு ஥஦க்கந்஡ான் ச஥த்஡க் கா஠ல் 
ச஡ாித஬ாடு த஡கச஥ங்கும் ச஬பிறுண் டா஡ல் 
த஡கச஥த்஡ ஬ாதனாதப் தடு஡ல் காத஠” 
                                   - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(24) 
 
COMMON SYMPTOMS: 
 Thirst, Polydipsia, Anorexia, Polyuria, Dyspnoea, Burning sensation, 
Sleeplessness, Giddiness, Flatulence, Anaemia, Loss of weight, Cough, Pain in the 
hip, Hiccough.                                                    
 
NOI VAGAIKAL - (CLASSIFICATION): 
Megarogam is classified into twenty varieties to quote from Agasthiar. 
“உட்டி஠ த஧ாகத்஡ாலும் உறும்சதய௃ம்தசி஦ிணாலுங்  
கட்ட஬ிழ் தகாக஡ ஥ா஡ர்கன஬ி஥ட்டினா க஥஦னாலு  
ப௃ட்டநா ஢ாலு஥ாறு ப௃ம்ப௄ன்று ச஥ான்று ச஥ன்று  
஡ிட்ட஥ாய் ஬ய௃஬ச஡ன்று ஡ிய௃஥ாப௃ணி ஦ய௃பிச் சசய்஡ார்” 
                                    - அகத்஡ி஦ர் 
(25)
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Yugi Munivar classifies the same as, 
“஬சணித்஡ த஥க஥து ஦ி஧ண்டு தத்து 
  ஬ா஡த்஡ிற் திநந்஡சனம் ஢ாதன ஦ாகும் 
திசணித்஡ தித்஡த்஡ிலு ற்நத ஬ித்஡ 
 தத஧ாண சனந்஡ாத௅ ஥ாறு ஥ாகும் 
ச஡சணிந்஡ தசட்டு஥த்஡ிலுற்த ஬ித்஡ 
 சீ஧ாண சனந்஡ாத௅ம் தத்த஡஦ாகும்” 
                                    - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(26) 
According to Theraiyar 
“க஫ியும் ஬ா஡ம் ஢ான்காலும் காயும் தித்஡ ஥ாநாலும் 
சு஫ியும் தசத்து஥ண் தத்஡ாலும் சசால்லும் ஢ானஞ்சாய் த஡ான்றும்” 
                                      - த஡க஧஦ர் ஬ாகடம் 
(27) 
 
NOI VAGAIGAL:  
         BOOKS NOI ENN VALI     AZHAL IYAM 
யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 20 4 6 10 
         அகத்஡ி஦ர் 1200 20 4 6 10 
       த஡க஧஦ர் ஬ாகடம் 20 4         6 10 
      ஡ன்஬ந்஡ிாி க஬த்஡ி஦ன் 20 4 6 10 
ச஧ததந்஡ி஧ ஢ீாி஫ிவு த஧ாக சிகிச்கச 20 4 6 10 
யூகி க஬த்஡ி஦ கா஬ி஦ம் 20 4 6 10 
 
The above books describe twenty different kinds of Megam (urinary disorders) 
on the basis of colour, consistency, taste, smell, weight etc. 
Out of these twenty different kinds, four varieties are caused by Vali, six varieties 
are caused by Azhal, ten varieties are caused by Iyam. 
Madhumegam comes under the classification of Azhal. 
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CLASSIFICATION OF MEGAM: 
According to Yugi Vaidhya Chinthamani, Yugi described  
four types under the Vatha premeham 
six types under the pitha prameham and 
ten types under Kaba prameham.  
 
VAADHA NEER VAGAIGAL: 
  “஡ாித்஡ிட்ட ஬ா஡த்஡ின் சனந்஡ா ணாலு 
 ஡ணி஦ாண ஢ாலுக்கும் ததத஧ ச஡ன்ணில் 
அாித்஡ிட்ட ஆச்சி஦சகந்஡ி த஥கத்த஡ாடு 
 அ஡ன்திநகு சுற்ந஥ா த஥கச஥ன்று 
திாித்஡ிட்ட தி஧஥ி஦ த஥கச஥ன்று 
 தத஧ாண ஥ாங்க஧஬ி த஥கச஥ன்று” 
                                  - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(28) 
VALI – 4 
1. Neimananeer 
2. Pasumana neer 
3. Seezhmana neer 
4. Sathaimana neer 
 
PITHA NEER VAGAIGAL: 
“ப௃கந஦ாண தித்஡ சன ஥ாறு஥ாகும் 
       ப௃஡ிர்ந்஡ அப்தி஦ ச஥ன்றும் தி஧஥ி஦ ச஥ன்றும் 
துகந஦ாண சாம்பீர்஠஥தும்த ச஥ன்றும் 
       சாத்஡ிகச஥ ஦ாறு஬ி஡ந் ஡ன்தணா டாறு” 
                                  - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(29)
  
AZHAL – 6 
1. Yanai kozhupu mana neer 
2. Katrazhai mana neer 
3. Chunna mana neer 
4. Innipu neer 
5. Palingu neer 
6. Muyal kurithi neer 
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 IYA NEER VAGAIGAL: 
“ஆநாண சிதனட்தசனம் தத்து ஡ன்கண 
அ஧ன் சசால்ன ஆத்஡ாள் ஡ான் தகட்கும் ததாது 
஬ாநாண ஬சாத஥கம் உத்சத஥கம் 
஥ச்சி஦ாத஥ கத்த஡ாத கீ஡ த஥கம் தூநாண சு஧ாாி சுக்ன ப௃த்஡ 
த஥கம் சுற்ந஥ாம்தி ணாணிச஦ாட ஬ன஠ த஥கண் 
தகநாண ச஡யுத்஡஦஥ா த஥க ச஥ன்று 
சசப்திணார் சிதனட் தத்஡ின் சசலுத்துத் ஡ாதண” 
                                   - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(30)                          
                                               
IYAM – 10 
1. Iaya Neer  
2. Thuimai Neer 
3. Moolai neer 
4. Ilaneer 
5. Kal neer 
6. Thavala Neer 
7. Kazhu neer 
8. Then neer 
9. Uppu neer 
10. Kavichi Neer 
  
NOIKURI KUNANGAL – (CLINICAL FEATURES) 
Polyuria, Polyphagia, Polydypsia, perspiration, exhaustion, insomnia, 
giddiness and loss of weight are seen even at normal consumption of food. 
 
COMMON SIGN AND SYMPTOMS OF PITHA PRAMEHAM: 
             “அநி஦த஬ தித்஡சன ஥ாறுக்குந்஡ான் 
                              அங்க஥஡ிற் சசய்கின்ந கு஠த்க஡க் தகபாய் 
               ஡நி஦த஬ சாீ஧ம் ஬ற்நி ச஦ாிவுங்டாகும் 
                              சடத்஡ிலுந் ஢ீாிலுந்஡ான் க஬ிச்சுண்டாகும் 
               ச஡நி஦த஬ சீப்ததாலுங் கற்நாக஫ ததாலும் 
                              தசல் ததாலும் த஡ன் ததாலும் ஢ாற்ந ப௃ண்டாம் 
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               ச஬நி஦த஬ பீசத்஡ிற் தகாசத்஡ிற் கு஡த்஡ில் 
                              ஥ிகு஥ீ஧ல் ஢ாதி஦ிலும் த஬க்கா டாத஥ 
               த஬க்காடாய் ஬ி஧஠ ப௃ண்டாய் ஬ாய்஡ான் ஢ாறும் 
                              ஬ிக்கசனாடு அய௃சி஦ா஦ச் சு஧ப௃ண்டாகும் 
                ஡ீக்காடாய்த் த஡கந்஡ான் கிகடசகாட்டாது 
                              ஡ி஦க்கச஥ாடு ப௄ர்ச்கசயுண்டா ஥஦க்க ஥ாகும் 
              
                             சாக்காடாய் ஢ா஬நந் ஡ண்஠ீந் ஡ாகம் 
                              சக்஡ிச஦ாடு சாீ஧ச஥ல்னாந் ஡பர்ச்சி ஦ாகும் 
               ஡ாக்கடா ஥னசஞ்சனந்஡ான் ஥ிகவுண்டாகும் 
                              ச஥கு஠ந்஡ான் தித்஡ சன ஥ாறு ஥ாச்தச” 
                                    - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(31) 
          As per the above poem, polyuria, polyphagia, polydipsia, fever, angular 
stomatitis, burning sensation all over the body, loss of weight, are common signs and 
symptoms of pitha prameham. 
 
MUKKUTRA IYAL: 
VALI : 
Sites of Vadha: 
    Below Naval, Urinary bladder, intestines, Pelvis, umbilical cord, thigh, bone, skin, 
nerve endings, joints, Musculature, hair root. 
Properties: 
    Dryness, Lightness, Clearness, Coolness, Mobile, Formless. 
Function: 
Praanan (Uyirkaal) : 
    This controls knowledge, mind and five sense organs, which are useful for 
breathing and digestion. 
Abaanan (Keezh nokku kaal) : 
    This is responsible for all down ward movements such as passing urine, stools, 
semen, menstrual flow etc 
Samaanan (Nadukkaal) : 
    This aids in proper digestion. 
Viyaanan (paravukaal): 
    This is responsible for all movements of all parts of the body. 
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Uthaanan (Mel Nokkukaal) : 
    Responsible for all upward visceral movements, such as vomiting, eructation and 
nausea. 
Naagan : 
    Responsible for opening and closing the eyes. 
Koorman : 
    Responsible for vision and yawning. 
Kirukaran : 
    Responsible for salivation, nasal secretion and appetite. 
` Devathatthan : 
    Responsible for Laziness, sleeping and anger. 
Thananjeyan : 
    Produces bloating of the body after death. It escapes on the third day after death 
bursting out of the cranium. 
In Madhumegam 
Piranan         :  Normal 
Abanan         :  Constipation, Noctural polyuria, frequency of micturation. 
Viyanan      :  Symmetrical sensory disturbances, peripheral neuritis, pain all over          
                           the body, burning sensation in the sole of foot and palm, Skin  
                           infection and carbuncle. 
Udanan         :  Normal 
Samanan       :  Poly Phagia 
Nagan           :  Normal 
Koorman      :  Diabeic Retinopathy, Cataract 
Kirukaran     :  Polyphagia 
Devathathan :  Normal 
Thananjeyan:   - 
 
AZHAL :  
Sites of Pitha: 
    Between the heart and the naval, sweat, lymph, blood, stomach, urinary bladder, 
heart, saliva, eyes and skin. 
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Properties:   
    Dry, cold, hot, light, subtle, keen, soft, liquid, bitter. 
Function 
1. Anal Pittham : It promotes appetite and helps in digestion. 
2. Ranjagam :      It gives colour to the blood. 
3. Praasagam :     It gives complexion to the skin. 
4. Aalosagam :    It brightens the eyes. 
5. Saathagam :    It controls the whole body. It has the property to fulfil all the 
activities which the mind desires. 
In Madhu megam 
Anala Pitham    -    Excess hunger 
Ranjaga pitham -    Pallor sometimes 
Alosagapitham  -    Dimness of vision 
Saathaga pitham-    Lassitude 
Prasaga pitham  -    Dry skin 
IYAM : 
Sites of Kapha: 
    Above the heart, stomach, fat, sperm, tongue, uvula, bone marrow, blood, nose, 
nerves, bones, large intestine, eyes, joints. 
Properties: 
    Heavy, cold, mild, watery, sweet and stable. 
Function: 
Avalambagam : 
          Lies in the lungs, controls the heart and other kabhams. 
Kilethagam : 
     Lies in the stomach, makes the food moist, soft and helps in digestion. 
Pothagam :  
    Responsible for identifying taste. 
Tharpagam :  
    Present in the head and responsible for the coolness of eyes. 
Santhigam : 
    Responsible for lubrication and free movements of joints. 
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In Madhumegam 
Avalambagam  - Normal 
Tharpagam       - Burning sensation in the eyes 
Santhigam        - Joint pain 
Kilethagam      - Excessive appetite 
Pothagam         - Normal 
 
SEVEN UDAL THATHUKKAL (PHYSICAL CONSTITUENTS) 
    Annamaya kosa is constituted by seven Thathus. They are the basic tissues of our 
body. 
Normal functions: 
Saram: 
    It is responsible for the growth and development. It keeps the individual in good 
spirit and it nourishes the blood. 
Senneer: 
    Blood imparts colour to the body and nourishes the muscle responsible for the 
ability, intellect of the individual. 
Oon: 
    It gives shape to the body according to the requirements for the physical activity, 
nourishes fat. 
Kozhuppu: 
    It helps in lubricating the different organs and maintains only matter of the body. 
Enbu: 
    Supports the system and responsible for posture and movements of the body. 
Moolai:  
    It fills the bony cavity, nourishes semen, imparts strength endurance and shining 
appearance. 
Sukkilam / Suronitham: 
    It is responsible for reproduction. In healthy people, they function in a harmony, 
while in diseased people, they are deranged. 
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In Madhumegam: 
Saaram            :    Tiredness, General weakness 
Senneer           :    Pallor 
Oon                 :   Emaciation 
Kozhuppu       :     Dry skin 
Enbu               :     Later stage due to infection it affects the bone and sometimes leads   
                               to amputation. 
Moolai            :     Affected in Chronic stage. 
Sukkilam / 
Suronitham     :     Impotence, Sexual urge is reduced. 
 So, in Madhumegam, Seven Udal Thathukkal are deranged. 
 
MUKKUTRA VERUPADUGAL (PATHOGENISIS): 
The disease Megaroham, due to external (or) internal causes affects balance in 
the ratio of vali, Azhal, Iyam. This imbalance affects the Keelnokkukal, which inturn 
affect the seven udal thathukkal. Saram gets affected and there is loss of appetite. 
Seeneer also get affected with the net result even if the patient eats more nourished 
food (polyphagia) there won’t be any improvement in health.  
An imbalance in pitham does imply an imbalance in other two kutrams too 
and causes derangement of dasa vayu and seven udal thathukkal which cause the 
disease and other complications. 
 
PINIARI MURAIMAI- (DIAGNOSIS): 
     Diagnostic methods in Siddha system are very unique and solely based on clinical 
acumen of the physician. 
 Poriyal Arithal (or) understanding by the five organs of perception (Mei, 
Vai, Kann, Mooku, Sevi). 
 Pulanal Arithal (or) understanding by the sense objects (Uraithal, 
Suvaithal, Parthal, Mugarthal and Kettal). 
 Vinadal (or) Interrogation. 
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Tools used by Siddha Physicians: 
 Kaandal (Perception) 
 Karuthal (Inference)  
 Urai (The instruction of the inspired) 
The application of these three is very extensive in diagnosis and treatment. 
 
ENN VAGAI THERVU (EIGHT TOOLS OF DIAGNOSIS):  
Naa: 
Colour of the tongue, size, shape, anomalies, surface, mobility and local lesion should 
be noted. Coating deposition of the tongue, increased salivation and dryness of the 
tongue. In Madhumegam, the tongue remains dry and at times black. 
Niram: 
Colour of the skin all over the body, a local region of affection, conjunctiva, tongue, 
nail bud and hair etc. 
                                  Vatha Udal - Black and Whitish colour 
                                  Pitha Udal - Yellow or Reddish colour 
                                  Kabha Udal - White or Golden colour 
                                  Thontha Udal - Mix of two udal colours. 
In Madhumegam, the colour of skin is different from original complexion, 
discoloured. 
Mozhi: 
Observation of speech and voice. 
In uncontrolled Madhumegam, which leads to cerebrovascular disorder, 
speech disorder sets in. 
Vizhi:
Colour, character, vision should be observed. 
In uncontrolled Madhumegam cataract set in last. 
In longstanding cases, the Madhumegam affects retina and causes diabetic 
retinopathy which is the major cause of blindness. 
Sparisam: 
Colour of the skin (Vali, Azhal, Iyya udal), Eruption, Hemorrhages, Ulcers, 
Boils, trophic changes in the skin can be identified. 
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Any changes in the internal organs can be noted by palpation (or) percussion. 
In Madhumegam, increased tendency for fungal infection like moniliasis and 
vulvities.  
In Madhumegam the skin is dry and pale. 
Malam: 
Quantity, colour, smell, froth should be observed. 
In Madhumegam, constipation sometimes yellowish loose stool are passed. 
Moothiram: 
Quantity colour froth smell and specific gravity of urine should be noted. 
Urine: 
Colour        : In Madhumegam it is clear and white. 
Specific Gravity : In Madhumegam, urine is thick in consistency like honey. 
Smell        : Honey like smell 
Froths        : In Madhumegam the urine is frothy at the time of urination. 
Deposits      : In Madhumegam few epithelial cells are present in urine. 
Normal quantity of adult urine is 750 – 2500 ml in 24 hours.  
Disturbing Polyuria at night (nocturia ) and Glucosuria ( the presence of sugar in 
urine) are present. 
 
NEER NIRAKKURI: 
             “அய௃ந்து ஥ாநி஧஡ப௃ம் அ஬ித஧ா஡஥஡ாய் 
அ~கல் அனர்஡ல் அகானவூன் ஡஬ிர்ந்஡஫ற் 
குற்நப஬ய௃ந்஡ி உநங்கி க஬ககந 
ஆடிக்கனசத் ஡ா஬ித஦ காது சதய் 
ச஡ாய௃ப௃கூர்த்஡க் ககனக்குட்தடு ஢ீாின் 
஢ிநக்குநி ச஢ய்க்குநி ஢ிய௃஥ித்஡ல் கடதண” 
                                       - த஢ாய் ஢ாடல் 
(32)        
 
COLLECTION OF SAMPLE URINE: 
           The patient must take well cooked food in the previous day. The intake must 
be proportionate to the degree of his appetite. Food intake should be taken, at 
appropriate time.   The patient must have sound sleep on the previous night. The urine 
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is collected on the dawn of the next day in a glass container and closed immediately to 
prevent contamination. This specimen must be examined with in one and half hours. 
This procedure should be follow strictly to get accurate observation of Neerkuri and 
Neikuri. 
 
NEIKKURI:   
“஢ிநக்குநிக் குக஧த்஡ ஢ிய௃஥ா஠ ஢ீாிற் 
சிநக்க ச஬ண்ச஠ய்த஦ார் சிறுதுபி ஢டு ஬ிடுத் 
ச஡ன்றுநத் ஡ிநந்ச஡ாலி த஦கா஡க஥த்஡஡ி 
ணின்ந஡ி஬கன ததாம் ச஢நி஬ி஫ி஦நிவும் 
சசன்நது புகலுந் சசய்஡ிக஦ யு஠த஧” 
                              - த஢ாய் ஢ாடல் 
(33)
  
The diagnosis and prognosis of deranged Mukkutrams are studied on the basis 
of the behaviour of a drop of gingelly oil gently droped on the surface of the urine 
kept in a wide vessel in the sunlight.                                                                                     
“ப௃த்ச஡ாத்து ஢ிற்கின் ச஥ா஫ி஬ச஡ன் கதத஥” 
                               - த஢ாய் ஢ாடல் 
(34)
 
In Madhumegam, the oil dropped in urine is like a pearl and if the oil spreads 
slowly, the prognosis of the disease is slow and good. 
 
NAADI: 
Pulse is the confirmatory diagnosis. 
In Madhumegam,                                                        
                    “இய௃஥ித஦ தித்஡ப௃ம் ஬ா஡ப௃ம் கூடில் 
஥ய௃வுசன த஥கம் ஬ாய௃஡ி ததானாகும்  
உய௃஬ம் த஬நாகு ப௃ண்டவுடன் காந்஡ிடும்  
உய௃கத஬ வூதணாடு உநிஞ்சி இணிக்குத஥” 
                                - ஡ிய௃ப௄னர் 
(35) 
Coupling of Azhal and vadha naadi causes excessive urine as vast as sea, loss 
of weight and polyphagia . 
Whe kabha merges with vadha, glucosuria, emaciation, anaemia develops. 
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“தார்த்஡ிடு ப௄ன்றும் த஡ிந்து ச஥லிந்து ஢ிற்கில் 
த஡ர்ந்஡ிடு த஥஬ந் த஡ான்நித஦ சதாய௃ந்஡ிச஥டீத௃஦ில்” 
                                 - ஡ிய௃ப௄னர் ஢ாடி 
(36) 
When all that three nadi’s runs in low volume, Diabetes develops. 
 
MADHUMEGA GUNAM: 
                        “இணிக்கின்ந ஬ா஡த் ஡ிகடதசாில் ஐ஦ந்஡ான் 
தணிக்கின்ந கள்ளுப் த஡ணிததால் ஢ீத஧ாடும் 
கணிக்கின்ந த஥ணி கக஧ந்து ச஬ளுப்ததறும் 
஡ணிக்கும் ஥துத஥கந் ஡ப்தாது ஐ஦த஥” 
                                 - ஡ிய௃ப௄னர் 
(37) 
The coupling of the Vali and Iya naadi, causes increase in urination, and 
diabetes develops. 
AVATHAIGAL – (COMPLICATIONS): 
“கா஠த஬ ப௃஡ன஬த்க஡ சாீ஧ந் ஡ாத௅ம் 
கண஥ாகப் தய௃த்஡ிறுகி ஢ீர்த்து ஬ா஧ம் 
த஬஠த஬ த஬ண்டாக்கி ஦கனம் தண்ணும்  
஥ிக்க ஬ி஧ண்டா஥஬த்க஡ ஬ிபம்தக் தகபாய் 
ப௄஠த஬ ப௄த்஡ி஧ப்பீ கடயு஥ாச் சுக்ன 
ப௃க஥ழுகித் த஡ஜசு஡ான் ஥ிகத஬ குன்றும் 
஢ா஠த஬ ப௄ன்நாகு ஥஬த்க஡க் குத்஡ான் 
஢ா஬஧ளும் ஬ாயு஬து ஥ீற்ய்ந் ஡ாதண 
 
஡ாணாண ஢ான஬த்க஡ ஦ங்க ஡ாகம் 
சன்ணி஦து தா஡ப௃ண்டா க஥ந்஡ ஬த்க஡த் 
த஡ணாண ஢ீர்சதய௃குந் ஡ாது ஢ஷ்டம்  
஢ிகன஦ாநா ஥஬த்க஡யுடற் கிகடசகாள் பாது 
ப௄ணாண ப௄ர்ச்கச஬ய௃ த஥஫ ஬த்க஡ 
஥ிக்க஬த஧ா சகஞ் சு஬ாசந்த஡க சாட்டி஦ம் 
ஏணாண எட்டா஬ ஡஬த்க஡ ஡ாதண 
எழுகி஧ந்஡ி திபக஬யுந்஡ான் ஥ிகவுண் டாத஥ 
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உண்டாகு ச஥ான்த஡ா ஥஬த்க஡க் தகபாய் 
஑ழுக்காண அ஡ிசா஧ங் கிய௃஥ி யுண்டாம் 
தண்தாண தத்஡ாந்஡ா ண஬த்க஡ தகபாய் 
தா஧஥ாம் ச஦ங்கண்டு த஧த்துக் தககும் 
ச஬ண்டாகு த஥கந்஡ா ணிய௃த துக்கும் 
஬ிபங்கி஦த஡ார் ஡ச஬஬த்க஡ ஬ித஧ஞ் சசான்தணாம் 
அண்டாகுஞ் சாத்஦஬ சாத்஦஥ி ஧ண்டும் 
அநிந்து சகாண்டு அட஬ாக஬஬ிழ்஡ஞ் சசய்ச஦” 
                                   - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி  
1. Obesity and enlargement of urethral orifice. 
     There is obstruction in urinary flow. 
     In, Modern literature obesity is the diabetogenic factor and it will produce insulin     
     resistance. 
2. Polyuria resulting in gradual diminition of sukkila thathu. Impotence may occur. 
    Dryness of the skin occur due to dehydration. 
3. Intense thirst and dryness of mouth due to polyuria 
    Flatulance and acute abdomen also common in diabetes due to diabetic keto 
acidosis. 
4. Delirium (Janni) may supervenses after dehydration. 
    It is one of the acute complication of diabetes mellitus in diabetic keto acidosis and     
    non-ketotic hyperosmolar coma.  
5. Polyuria and loss of sukkila thathu are seen. 
    Impotence and retrograde ejaculation are common in diabetic patients due to          
    autonomic nervous system involvement.  
6. Restlessness is present.  
    There is Kussmaul’s air hunger with hissing type of respiration are seen.  
7. Ageusia, dysphagia, exhaustion are seen. 
8. Abscess and carbuncles are formed. 
9. Diarrhoea nocturnal in type. 
    Recurrent infection may occur. 
10.Tuberculosis and acute infections may lead to death. 
The above complications occur one by one in unidentified or improper 
treatment of Madhumegam. 
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Other complications of Madhumegam: 
Meganeer Kattigal (Diabetic Carbuncle) 
1. Madaku Katti 
2. Ammaiodu Katti 
3. Valai Kann Katti 
4. Athomuga Katti 
5. Paisura Katti 
6. Kadalai Katti 
7. Kadugu Katti 
8. Thirathi Katti 
9. Nilapoosani Katti 
10. Megavithirathi Katti 
 
PROGNOSIS (஡ீய௃ம் ஡ீ஧ா஡க஬): 
            “சசய்஦த஬ ஬ச்ச஧஥ாந் ஡ண்ட ஥ாண 
சசய்஥ாண ப௃துகு஡ண்கடப் தற்நி ஢ிற்கும் 
சதய்஦த஬ சதய௃஢஧ம்தில் த஥கந்஡ாத௅ம் 
திநக்கும்ச஥ன்தந ஡ாணநி ந்து ஬ா஡ந்஡ன்ணால் 
திய்஦த஬ திநந்஡சனம் ஢ான சாத்஡ி஦ம் 
தித்஡த்஡ிற் திநந்஡சன ஥ாறும் ஦ாப்஦ம் 
கத஦த஬ தசட்டு஥த்஡ிற் திநந்஡சனம் தத்தும் 
த஧஥த௅க஧த் ஡ார் சாத்஦ம் த஧ாத ாிக்தக” 
                                - யூகி க஬த்஡ி஦ சிந்஡஥஠ி 
(38) 
 
               “஬஫ியும் ஬ா஡ம் ஢ான்காத஥ ஥ாநா ஡஬ிடி஢஡ந் ஡ன்ணாதன 
சதா஫ியும் ஬ா஡ம் ஢ில்னாது ததாத஥ ஥ய௃ந்க஡ சதாய்ச஦ணத஬” 
                                     - த஡க஧஦ர் ஬ாகடம் 
(39)                                    
The four types of Megam caused as a result of imbalance of Vali are 
incurable. 
The six types of Megam arising with disparity of Azhal could be cured with 
great difficulty. 
But, ten types of megam arising due to Iyyam are curable. 
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ஏந்ச஡ந்஡ த஧ாகங்கபில் சிறு஢ீர் அ஡ிகாித்஡ாலும் குகநந்஡ாலும் ஡ீது ? 
 
              “ச஬ப்பு தி஠ி஦஡ணில் ச஬ம்த஥கத்஡ால் ஬ய௃ந்஡ின் 
஡ப்பு ஥ிகக ஢ீத஧ ஡ாணிநங்கின் – சசப்பும் 
கி஧ா஠ி஦ிற் தாண்டில் குபிர்஢ீர் சுய௃ங்கிற் 
தி஧ா஠ன் திாியுச஥ணப் ததசு” 
                                - கண்ணுசா஥ி஦ம் 
(40) 
Excess of urination in Megaroham causes death. 
 
“து஡ிப்தாண த஥கத்஡ில் ஢ீாி஫ிவு ஥ாகா 
த஡ான்நி஦ ஢ீாி஫ிவு ஡ண்஠ீர் ஬ா஡ப௃஥ாகா” 
                                  - ச஡க ஢ாடி 
(41)  
If Megaroham is associated with excessive urination, it is difficult to cure. If 
Megaroham coexist with vali, it is incurable.                   
                    
 “த஥கத்஡ில் ஢ீாி஫ிவு த஥வு஥஡ில் ஬ா஡த஢ாய் 
த஬க ஬஦ித்துள் ஬஦ிற்றுகபவு – தசாக ஬ிக்கல் தன்த௅ ஬ிக்கல் 
஡ன்ணில் தகககபப்புப் தாங்க ஡ணிற் 
தின்ணகப ஦ாகாது ததசு” 
                            - த஢ாய் ஢ாடல் 
(42)
                                
In Megaroham complications associated with carbuncle, Morbid thirst, excessive 
body heat, shock and sweat occurs and the prognosis will be bad. 
                          “த஬ர்க஬஡ணிற் கதப௃ம் த஥வு஥஡ில் ஬ிக்கல் த஢ாய் 
கார்ப௃கில் த஢ர் கூந்஡னா ய்கண்டு த஥ல் – சீர்சகாள் 
஥ய௃த்து஬த்஡ிற்தநர்ந்஡ ஥஡ியுகட஦ா஧ா஬ி 
஡ாித்஡ி஧ா ச஡ன்தர்சாி” 
                                 - த஢ாய் ஢ாடல் 
If Iya megam is associated with sweat hiccough, the prognosis is bad. 
 
த஥கம் இய௃ததுக்கும் தத்஡ி஦ம் : 
                             “த஥க ஥ிய௃ததுக்கும் தத்஡ி ஦ந்஡ான் 
தாங்காக எய௃க஥ த஥ார் சதான்ணாங்கா஠ி 
ததர்சதற்ந சிறுகீக஧ ப௃சுட்கட ஦ாகும் 
ஆாி஬ாக அ஬க஧ச஦ாடு புடல் ப௃ய௃ங்கக 
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அ஡ிச஧஥ாங் கண்டு சய௃க் கக஧யு ஥ாகும் 
஥ாி஬ாக ஥ா஡கப஦ாம் ததாீத் ஡ாகும் 
஥கா஬ிபம் த஫ப௃ந்஡ிாிப் த஫ப௃ ஥ாத஥ 
ஆத஥தத ஦ன் ஬ாக஫ப் த஫ப௃ங் கச்சல் 
அத்஡ி஦ிடப் திஞ்சுசிறு த஦றுத஫ஞ் தசாறு 
தாத஥த஫ஞ் தசாற்று஢ீர் ச஬ந்஡஦ஞ் சீ஧க஥ாம் 
தாகல் பீர்க் கங்காய்கய௃ த஬ப்திகன சகாத்஡஥ல்லி  
த஢த஥ச஢ற் சதாநி எள்ளு ப௃சுப௃சுக்கக ஦ாகும் 
த஢஧ாண ஢ல்சனண்ச஠ய் புண்஠க்குளுந்து 
஡ாத஥க ஥ிய௃ததுக்கும் தத்஦ ஬ர்க்கம் 
சாற்நிணார் சி஬ன்நாத௅ந் ஡ாய்க்கும் ஡ாதண” 
                                  - யூகி க஬த்஡ி஦ சிந்஡ா஥஠ி 
(43)
      
The following foods are preferred for Madhumegam: 
சதான்ணாங்கா஠ி, சிறுகீக஧, சகாத்஡஥ல்லி, ப௃சுப௃சுக்கக, பீர்க்கு, கய௃த஬ப்திகன, 
தாகல், அ஬க஧, ப௃ய௃ங்கக, ச஬ந்஡஦ம், சீ஧கம், எள், தசு஬ின்ச஬ண்ச஠ய், எய௃க஥ த஥ார், 
சிறுத஦று, உளுந்து  இக஬ த஥கம் இய௃ததுக்கும் தத்஡ி஦ம் ஆகும்.  
 
MARUTHUVAM: 
The treatment in Siddha Medicine is aimed at keeping the three kutrams (Vali, 
Azhal and Iyam) in equilibrium and maintenance of the seven udal thathukal. 
“உற்நா ணபவும் தி஠ி஦பவும் கானப௃ங் 
 கற்நான் கய௃஡ிச் சச஦ல்” 
                                   - ஡ிய௃க்குநள் 
A physician must have good knowledge about the patient, the disease, the 
duration of the disease and seasons in which symptoms get aggravate.                                                                                                               
 In Siddha science, the treatment is not only for removal of the disease, but for 
the prevention and improving the body condition after the removal of the disease. 
This is classified as Kappu (Prevention), Neekam (Treatment) and Niraivu 
(Restoration). 
KAPPU: 
        Prevention is better than cure  
                                                                               - Proverb. 
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           Siddha principles based mainly on prevention as mentioned in “Theraiyar pini 
Annuga vithi” by Theraiyar. The aim of the treatment is to bring the affected thathus 
and Mukkutram to normal levels by eyamma, niyamma, diet and medicine. 
 
NEEKAM: 
           For the disease Madhumegam, PERUNGAYA CHOORANAM - 2gm twice a 
day is given. 
 
NIRAIVU: 
Physical, Psychological, social and economic rehabilitation of individual is 
known as Niraivu. 
In Madhumegam, Azhal kutram and other two kutrams Vali and Iyam 
deranged and causes impairment of dasavayu which in turn affect the seven udal 
thathukkal.  
 
LINE OF TREATMENT: 
 “தகர்தித்஡ ஬ிந்க஡஦னாது த஥கம் ஬஧ாது” 
                                                       - த஢ாய் ஢ாடல் 
(44) 
So the treatment must be done to correct Azhal and then to correct the other 
two kutram Vali and Iyam. 
 
PHYSICAL EXCERCISES :      
                        “஢ண்பு சதந வுண்ட தின்பு குறு஢கடயுங் சகாள்த஬ாம்” 
                                      - த஡ார்த்஡ கு஠ சிந்஡ா஥஠ி 
(45) 
 The need for walking is emphasized by Theraiyar.  
            Exercise forms an important component along with drugs and diet 
management of Diabetes Mellitus – Type II. 
            Patients should be encouraged to take regular physical activity in form of brisk 
walking, gardening, swimming and cycling for 30 minutes daily to improve insulin 
sensitivity and maintain blood pressure. 
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YOGA FOR MADHUMEGAM: 
YOGA:  
      Yogic Physical exercise makes the muscles healthy and strong. It also tones up 
all the involuntary organs which are concerned digestion, evacuation, circulation, 
respiration and secretion and through them, the autonomic nervous system which 
regulates their activities. 
                                                                       - Yoga Aganas for Health & Vigour    
      Yoga is primarily the process of self-culture. Yoga according to Thirumandiram is 
the attainment of spiritual, psychological and physical perfection. 
“உடம்தா ன஫ி஦ில் உ஦ி஧ான஫ி஬ர் 
 ஡ிடம்தட ச஥ய்ஞணம் தச஧வும் ஥ாட்டார் 
உடம்கத ஬பர்க்கும் உதா஦ம் அநிந்த஡ 
உடம்கத ஬பர்த஡ன் உ஦ிர் ஬பர்த஡தண”  
                                                      - ஡ிய௃ப௄னர் 
(1) 
      As a body is said to be divine, Thirumoolar advised that each and every individual 
aspiring for self realisation should practice yoga. It is a science that helps to lead a 
pure and healthy life, the practice of yoga prevents the decay of tissues by increasing 
with abundant energy force. 
 “இ஦஥ம் ஢ி஦஥ம் எண்஠ினா ஆ஡ணம் 
 ஢஦ப௃று தி஧ா஠ா஦ா஥ம் தி஧த்஡ி஦ாகா஧ம் 
 ச஦ப௃று ஡ா஧க஠ ஡ி஦ாணம் ச஥ா஡ி 
 அ஦ப௃று அட்டாங்க ஥ா஬து ஥ாத஥ 
      - திருமூலர ்(46) 
 Asanas are nothing but a kind of yoga. There are innumerable types asanaas 
described in Siddha text. Each and every yogasana is indicated for a definite effect in 
a particular region of the body by stimulating the internal organs to function in a 
normal way. 
 
The following Asanaas will help to manage madhumegam:  
1. Dhanurasanam 
2. Paschimottanasanam 
3. Pawanamukthasanam 
4. Ardha Matsyendrasanam 
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1. Dhanurasanam 
Dhanurasanam has been named after the shape the body takes while 
performing it that of a bow. Dhanu means bow.  
 
Practice: 
1. Lie on your stomach with your feet hip-width apart and your arms by the side of   
your body. 
2. Fold your knees, take your hands backwards and hold your ankles. 
3. Breathing in, lift your chest off the ground and pull your legs up and back. 
4. Look straight ahead with a smile on your face. 
5. Keep the pose stable while paying attention to your breath. Your body is now 
curved and taut as a bow. 
6. Continue to take long deep breaths as you relax in this pose. But bend only as far as 
your body permits you to. Do not overdo the stretch. 
7. After 15 -20 seconds, as you exhale, gently bring your legs and chest to the ground. 
Release the ankles and relax. 
Benefits: 
          Helps regulate the pancreas and is recommended for people with diabetes. 
 
2. Paschimottanasanam 
 “Paschima” means your “back” and “Uttana” means “stretching“. This asan 
coversthe stretching of the whole body from head to heels so it is called as 
Paschimottanasnam. 
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Practice: 
1. Sit down straight with your legs together by stretching in front of you. keep your 
head neck and spine erect. 
2. Place the palms on your respective knees. 
3. Now bend your head and trunk slowly forward to catch the toes with the thumb, 
index and middle fingers without bending knees. 
4. Take a deep breath and exhale slowly. Try to touch your head to your both knees as 
shown in above image. 
5. Bend the arm and try to touch the elbow on the floor. 
6. Exhale completely and holding out your breath stay in this posture for a few 
seconds. 
7. After few seconds slowly return to your starting position. 
8. Breathe normally. 
9. Repeat this for 3-4 times. 
Benefits: 
1. It acts as a stress reliever. 
2. Reduces fatty deposits in the abdomen. 
3. Remove anxiety, anger and irritability. 
4. It induces the pancreas and helps in preventing diabetes. 
 
3. Pawana muktasanam 
Pawana muktasanam knows as Wind Removing Pose. It is beneficial to curen 
gas problems and poor digestion. Regular practice of Pawanamuktasanam helps to 
stimulate bowel movement which is very necessary for removing waste material.     
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Practice: 
1. Lie flat on your back and keep the legs straight and relax breathe deeply and 
rhythmically. 
2. Inhale slowly and lift the legs and bend in the knee. Bring upwards to the chest till 
your thigh touches to stomach 
3. Hug your knees in place and lock your fingers. 
4. Try to touch the knee with your nose tip. This is not easy in first time. But regular 
practice you can do this. Hold this position for 20 to 30 seconds. You can extend it till 
1 minute as per your capability. 
5. Now exhale slowly and come back to the original position that is Shavasana (Lie 
straight) 
6. This is very beneficial for stomach abs. The results are very impressive. 
7. Practice 3 to 5 cycles each day. 
Benefits: 
1. Cures acidity Indigestion and Constipation. 
2. Very good for all abdominal organs. 
3. Regular practice cures gastrointestinal problems. 
4. It induces the pancreas and helps in preventing diabetes. 
 
4. Ardha matsyendrasana 
  Ardha means Half, Matsyendra means King of fish. 
 
Practice: 
Sit with the legs straight and relax the whole body. 
Place the sole of the right foot flat on the floor on the outside of the left knee. 
Bend the left leg and lay the left heel beside the right buttock. Both buttocks remain 
on the floor. The back is upright and relaxed. 
Bring the left arm to the outside of the right knee and grasp the right ankle. 
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Turn the upper body as far as possible to the right, place the right arm across the 
back and look over the right shoulder. Breathing normally remains for a few minutes 
in this position and relax the whole body. 
hen slowly return to the starting position. 
Benefits: 
1. Promotes mobility of the spine and hips. 
2. The twist aids release of tension from the deep layers of muscle in the back. 
3. The breath is also deepened in this position. 
4. Function of the kidneys and pancreas is stimulated and the ability to concentrate is 
improved.  
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MODERN ASPECT 
 
DEFINITION: 
            Diabetes Mellitus is a group of metabolic disorder characterized by 
Hyperglycemia resulting from defects in Insulin secretion, Insulin action, or both. The 
chronic Hyperglycemia of Diabetes is associated with long-term damage, dysfunction, 
and failure of different organs, especially the eyes, kidneys, nerves, heart and blood 
vessels. 
            Several pathogenic processes are involved in the development of Diabetes. 
These range from autoimmune destruction of the β-cells of the Pancreas with 
consequent Insulin deficiency to abnormalities that result in resistance to Insulin 
action. The basis of the abnormalities in Carbohydrate, Fat and Proteins metabolism 
in Diabetes is deficient action of Insulin on target tissues. Deficient Insulin action 
results from inadequate Insulin secretion or diminished tissue responses to Insulin at 
one or more points in the complex pathways of hormone action. Impairment of Insulin 
secretion and action frequently coexist in the same patient, and it is often unclear 
which abnormality, if either alone, is the primary cause of the hyperglycemia 
(47)
.  
 
EPIDEMIOLOGY: 
            The application of Epidemiology to the study of Diabetes Mellitus has 
provided valuable information on several aspects of this disease such as its natural 
history, prevalence, incidence, morbidity and mortality in diverse populations around 
the world. Identification of the cause of the disease and the possible preventive 
measures that could be instituted to arrest or delay the onset of this disease which has 
reached epidemic proportions in both the developed and the developing nations. 
Unfortunately, the improvement in outcomes for individual patients with Diabetes has 
not resulted in similar improvements from the public health perspective.  
             Diabetes is fast gaining the status of a potential Epidemic in India with more 
than 62 million Diabetic individuals currently diagnosed with the disease. The 
prevalence of Diabetes is predicted to double globally from 171 million in 2000 to 
366 million in 2030 with a maximum increase in India. It is predicted that, by 2030 
Diabetes Mellitus may afflict up to 79.4 million individuals in India, while China 
(42.3 million) and the United States (30.3 million) will also see significant increase in 
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those affected by the disorder 
(48).
 The WHO-ICMR national NCD risk surveillance 
study reported an overall frequency of self-reported diabetes of 4.5% with urban 
population scoring (7.3%), over the rural areas (3.1%) 
(49)
 
               India currently faces an uncertain future in relation to the potential burden 
that Diabetes may impose upon the country. Many influences affect the prevalence of 
disease throughout a country, and identification of those factors is necessary to 
facilitate change when facing health challenges 
(50)
. 
 
ETIOLOGY: 
 Type I Diabetes occurs when your immune system, the body‟s system for 
fighting infection, attacks and destroys the Insulin-producing beta cells of the 
Pancreas. Type I Diabetes is caused by genes and environmental factors, such as 
viruses, that might trigger the disorder. 
 Type II Diabetes is the most common form of Diabetes and it is caused by 
Several factors, including lifestyle factors and genes. 
 Gestational Diabetes is a type of Diabetes that develops during pregnancy, and 
is caused by the hormonal changes of pregnancy along with genetic and lifestyle 
factors 
(51)
. 
  
OTHER CAUSES: 
GENETIC MUTATIONS: 
 Monogenic Diabetes is caused by mutations, or changes, in a single gene. 
These changes are usually passed through families, but sometimes the gene mutation 
happens on its own. Most of these gene mutations cause Diabetes by making the 
Pancreas less able to make Insulin. The most common types of monogenic Diabetes 
are Neonatal Diabetes and Maturity-Onset Diabetes of the Young (MODY). Neonatal 
Diabetes occurs in the first 6 months of life. 
 Cystic Fibrosis produces thick mucus that causes scarring in the Pancreas. 
This scarring can prevent the Pancreas from making enough Insulin. 
 Hemochromatosis causes the body to store too much iron. If the disease is not 
treated, iron can build up in and damage the Pancreas and other organs. 
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HORMONAL DISEASES: 
  Some hormonal diseases cause the body to produce too much of certain 
hormones, which sometimes cause Insulin resistance and Diabetes. 
Cushing‟s syndrome occurs when the body produces too much Cortisol and often 
called the “Stress hormone.” Acromegaly occurs when the body produces too much 
growth hormone. Hyperthyroidism occurs when the thyroid gland produces too much 
thyroid hormone. 
DAMAGE OR REMOVAL OF THE PANCREAS: 
        Pancreatitis, pancreatic cancer and trauma can all harm the beta cells or make 
them less able to produce Insulin, resulting in Diabetes. If the damaged Pancreas is 
removed, Diabetes will occur due to the loss of the beta cells 
(52)
.  
 
PATHOPHYSIOLOGY: 
        There is a direct link between Hyperglycaemia and physiological and 
behavioural responses. Whenever there is Hyperglycaemia, the brain recognizes it and 
sends a message through nerve impulses to Pancreas and other organs to decrease its 
effect. 
TYPE I DIABETES MELLITUS: 
        Type I Diabetes is characterized by autoimmune destruction of Insulin producing 
cells in the Pancreas by CD4+ and CD8+ T cells and macrophages infiltrating the 
Islets. Several features characterize Type I Diabetes Mellitus as an autoimmune 
disease. 
1. Presence of immuno-competent and accessory cells in infiltrated Pancreatic 
Islets. 
2. Association of susceptibility to disease with the class II (immune response) 
genes of the major histocompatibility complex (MHC; Human Leucocyte 
Antigens HLA). 
3. Presence of Islet cell specific autoantibodies. 
4. Alterations of T cell mediated immune regulation, particularly in CD4+ T 
cell compartment. 
5. The involvement of monokines and TH1 cells produce inginterleukins  in 
the disease process. 
6. Response to immunotherapy 
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7. Frequent occurrence of other organ specific auto- immune diseases in 
affected individuals or in their family members. 
 Approximately 85% of patients have circulating islet cell antibodies, and the 
majorities also have detectable anti-Insulin antibodies before receiving Insulin 
therapy. Most Islet cell antibodies are directed against Glutamic Acid Decarboxylase 
(GAD) within pancreatic β cells. 
TYPE II DIABETESMELLITUS: 
 The two main pathological defects in Type II Diabetes are impaired Insulin 
secretion through a dysfunction of the pancreatic β-cell, and impaired Insulin action 
through Insulin resistance. In situations where resistance to Insulin predominates, the 
mass of β-cells undergoes a transformation capable of increasing the Insulin supply 
and compensating for the excessive and anomalous demand. 
         In absolute terms, the plasma Insulin concentration (both fasting and meal 
stimulated) usually is increased but although relative to the severity of Insulin 
resistance, the plasma Insulin concentration is insufficient to maintain normal Glucose 
Homeostasis. Keeping in mind the intimate relationship between the secretion of 
Insulin and the sensitivity of hormone action in the complicated control of Glucose 
Homeostasis, it is practically impossible to separate the contribution of each to the 
etiopathogenesis of Diabetes Mellitus type II. 
         Insulin resistance and Hyper Insulinemia eventually lead to Impaired Glucose 
Tolerance. Except for Maturity Onset Diabetes of the Young(MODY), the mode of 
inheritance for Type II Diabetes Mellitus is unclear. MODY, inherited as an 
autosomal dominant trait, may result from mutations in Glucokinase gene on 
chromosome 7p. MODY is defined as Hyperglycaemia diagnosed before the age of 
twenty-five years and treatable for over five years without Insulin in cases where Islet 
cell antibodies (ICA) are negative. 
INSULIN RESISTANCE: 
         The primary events are believed to be an initial deficit in Insulin secretion and in 
many patients relative Insulin deficiency in association with peripheral Insulin 
resistance. Resistance to the action of Insulin will result in impaired Insulin mediated 
glucose uptake in the periphery (by muscle and fat), incomplete suppression of 
hepatic glucose output and impaired triglyceride uptake by fat. To overcome the 
Insulin resistance, Islet cells will increase the amount of Insulin secreted. Endogenous 
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glucose production is accelerated in patients with Type II Diabetes or Impaired 
Fasting Glucose. Because this increase occurs in the presence of Hyper Insulinemia, 
at least in the early and intermediate disease stages, hepatic Insulin resistance is the 
driving force of Hyperglycemia of Type II Diabetes 
(53)
.  
 
THE PANCREAS: 
         The Pancreas is an Abdominal Glandular organ, with a Digestive (Exocrine) and 
Hormonal (Endocrine) function. 
ANATOMICAL POSITION: 
         The Pancreas is an oblong-shaped and flattened organ, about the size of a hand. 
Aside from the tail, it is a Retroperitoneal structure (lies behind the peritoneal cavity), 
located deep within the upper abdomen in the epigastrium and left hypochodrium 
regions. 
Within the abdomen, the Pancreas is surrounded by other viscera and vessels. 
 Stomach – lies Anteriorly and Superiorly. 
 Duodenum – situated Anteriorly and Medially, curving around the head of the 
Pancreas. 
 Spleen – located Posteriorly and Laterally. It is connected by ligaments to the 
tail of the Pancreas. 
 Vasculature – the Aorta and Inferior vena cava pass Posteriorly to the head of 
the Pancreas. 
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ANTERIOR VIEW OF ABDOMEN: 
ANATOMICAL STRUCTURE: 
         The Pancreas is typically divided into five parts: 
  1. Head: 
This is the widest part of the Pancreas. It lies within the C-shaped curve 
created by the Duodenum, and is connected to it by connective tissue. 
2. Uncinate process: 
This is a projection arising from the lower part of the head and extending 
medially to lie beneath the body of the Pancreas. It lies posterior to the 
superior mesenteric vessels. 
3. Neck: 
It is located between the head and body of the Pancreas. It overlies the 
superior Mesenteric vessels which form a groove in its posterior aspect. 
4. Body: 
The body is centrally located, crossing the midline of the human body to lie 
behind the Stomach and to the left of the Superior Mesenteric vessels. 
5. Tail: 
The left end of the Pancreas that lies within close proximity to the hilum of the 
Spleen. It is contained within the Spleno -renal ligament with the Splenic 
vessels. This is the only part of the Pancreas that is intraperitoneal. 
PARTS OF THE PANCREAS 
                                                    
 
 
THE DUCT SYSTEM: 
         The Exocrine compartment is classified as a serous gland. It is composed of 
approximately a million „Berry-like‟ clusters of cells called Acini, connected by short 
intercalated ducts. 
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         Intercalated duct cells beginning within Acini are called Centroacinar cells. The 
intercalated ducts drain into a network of intralobular collecting ducts, which in turn 
drain into the main Pancreatic duct. 
         The Pancreatic duct runs the length of the Pancreas and unites with the common 
bile duct, forming the Hepato-pancreatic Ampulla of Vater. This structure opens into 
the Duodenum.       
         Secretions into the Duodenum are controlled by a muscular valve, the sphincter 
of Oddi. It surrounds the Ampulla of Vater, acting as a valve. 
 
EXOCRINE PANCREAS SECRETING INTO THE DUODENUM: 
VASCULATURE: 
         The Pancreas is supplied by the pancreatic branches of the Splenic artery. The 
head is additionally supplied by the superior and inferior Pancreatico-duodenal 
arteries which are branches of the Gastro-duodenal and superior Mesenteric arteries, 
respectively. 
         Venous drainage of the head of the Pancreas is into the superior Mesenteric 
branches of the Hepatic portal vein. The Pancreatic veins draining the rest of the 
Pancreas do so into the splenic vein. 
 
THE ARTERIAL SUPPLY AND VENOUS DRAINAGE OF THE PANCREAS 
                                            
 
LYMPHATICS: 
         The Pancreas is drained by lymphatic vessels that follow the arterial supply. 
They empty into the Pancreatico- Splenal nodes and the pyloric nodes, which in turn 
drain into the superior Mesenteric and Celiac lymph nodes. 
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CELLS AND SECRETIONS OF THE PANCREATIC ISLETS: 
The Pancreatic Islets each contain four varieties of cells: 
       1. The alpha cell produces the hormone Glucagon and makes up 
approximately 20 percent of each Islet. Glucagon plays an important role in 
blood Glucose regulation; low blood glucose levels stimulate its release. 
       2. The beta cell produces the hormone Insulin and makes up 
approximately 75 percent of each Islet. Elevated blood Glucose levels 
stimulate the release of Insulin. 
        3. The delta cell accounts for four percent of the Islet cells and secretes 
the peptide hormone Somatostatin. It is also released by the hypothalamus (as 
GHIH). Pancreatic Somatostatin inhibits the release of both Glucagon and 
Insulin. 
        4. The Pancreatic polypeptide cell accounts for about one percent of Islet 
cells and secretes the pancreatic polypeptide hormone. It is thought to play a 
role in appetite, as well as in the regulation of Pancreatic Exocrine and 
Endocrine secretions. Pancreatic polypeptide released following a meal may 
reduce further food consumption; however, it is also released in response to 
fasting. 
REGULATION OF BLOOD GLUCOSE LEVELS BY INSULIN AND 
GLUCAGON: 
          Glucose is required for cellular respiration and is the preferred fuel for all 
body cells. The body derives glucose from the breakdown of the carbohydrate 
containing foods and drinks. Glucose not immediately taken up by cells for fuel can 
be stored by the liver and muscles as Glycogen, or converted to Triglycerides and 
stored in the adipose tissue. Hormones regulate both the storage and the utilization of 
glucose as required. Receptors located in the Pancreas sense blood glucose levels, and 
subsequently the pancreatic cells secrete Glucagon or Insulin to maintain normal 
levels. 
GLUCAGON: 
 Receptors in the Pancreas can sense the decline in blood glucose levels, such 
as during periods of fasting or during prolonged labour or exercise. In response, the 
alpha cells of the Pancreas secrete the hormone Glucagon, which has several effects: 
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 It stimulates the liver to convert its stores of glycogen back into glucose. This 
response is known as Glycogenolysis. The glucose is then released into the circulation 
for use by body cells. 
   It stimulates the liver to take up amino acids from the blood and convert them 
into glucose. This response is known as Gluconeogenesis. 
  It stimulates Lipolysis, the breakdown of stored Triglycerides into free Fatty 
acids and Glycerol. Some of the free glycerol released into the bloodstream travels to 
the liver, which converts it into glucose. This is also a form of Gluconeogenesis. 
        These actions increase blood glucose levels. The activity of Glucagon is 
regulated through a Negative feedback mechanism; rising blood glucose levels inhibit 
further Glucagon production and secretion. 
INSULIN: 
         The primary function of Insulin is to facilitate the uptake of glucose into body 
cells. Red blood cells, as well as cells of the brain, liver, kidneys, and the lining of the 
small intestine, do not have Insulin receptors on their cell membranes and do not 
require Insulin for glucose uptake. Although all other body cells do require Insulin if 
they are to take glucose from the bloodstream, skeletal muscle cells and adipose cells 
are the primary targets of Insulin. 
         The presence of food in the intestine triggers the release of gastrointestinal tract 
hormones such as glucose-dependent insulin tropic peptide (previously known as 
Gastric inhibitory peptide). This is in turn the initial trigger for Insulin production and 
secretion by the beta cells of the Pancreas. Once nutrient absorption occurs, the 
resulting surge in blood glucose levels further stimulates Insulin secretion. 
          Precisely how Insulin facilitates glucose uptake is not entirely clear. However, 
insulin appears to activate a Tyrosine kinase receptor, triggering the phosphorylation 
of many substrates within the cell. These multiple biochemical reactions converge to 
support the movement of intracellular vesicles containing facilitative glucose 
transporters to the cell membrane. In the absence of Insulin, these transport proteins 
are normally recycled slowly between the cell membrane and cell interior. Insulin 
triggers the rapid movement of a pool of glucose transporter vesicles to the cell 
membrane, where they fuse and expose the glucose transporters to the extracellular 
fluid. The transporters then move glucose by facilitated diffusion into the cell 
interior
(54)
.  
                                                                                                MODERN ASPECT 
 
 
 
Page 43 
 
  
CLASSIFICATION 
         The new classification is primarily based on etiologies. The staging of 
pathophysiology by degree of deficiency of insulin is also adopted. The previous 
terms, insulin-dependent diabetes mellitus (IDDM) and non-insulin dependent 
diabetes mellitus (NIDDM), are abandoned. Instead, the terms type 1 and type 2 
diabetes mellitus are used for etiological classification. The etiologic classifications of 
Diabetes Mellitus are listed below. 
TYPE I DIABETES: 
         Type I Diabetes Mellitus (Juvenile Diabetes) is characterized by beta cell 
destruction caused by an autoimmune process, usually leading to absolute Insulin 
deficiency. Type I is usually characterized by the presence of anti–glutamic acid 
decarboxylase, Islet cell or Insulin antibodies which identify the autoimmune 
processes that lead to beta cell destruction. 
IMMUNE-MEDIATED DIABETES: 
         This form of Diabetes, which accounts for only 5–10% of those with Diabetes, 
previously encompassed by the terms Insulin-Dependent Diabetes. Type I Diabetes or 
Juvenile-onset Diabetes, results from a cellular-mediated autoimmune destruction of 
the β-cells of the Pancreas. 
          In this form of Diabetes, the rate of β-cell destruction is quite variable, being 
rapid in some individuals (mainly infants and children) and slow in others (mainly 
adults). Some patients, particularly children and adolescents, may present with 
ketoacidosis as the first manifestation of the disease. Others have modest fasting 
hyperglycemia that can rapidly change to severe Hyperglycemia and/or ketoacidosis 
in the presence of infection or other stress. 
IDIOPATHIC DIABETES: 
         Some forms of Type I Diabetes have no known etiologies. Some of these 
patients have permanent insulinopenia and are prone to ketoacidosis, but have no 
evidence of autoimmunity. Although only a minority of patients with Type I Diabetes 
fall into this category most are of African or Asian ancestry. Individuals with this 
form of Diabetes suffer from episodic Ketoacidosis and exhibit varying degrees of 
insulin deficiency between episodes. 
 
 
                                                                                                MODERN ASPECT 
 
 
 
Page 44 
 
  
TYPE II DIABETES MELLITUS: 
         This form of Diabetes, which accounts for approximately 90–95% of those with 
Diabetes, previously referred to as Non–Insulin-Dependent Diabetes, Type II 
Diabetes, or Adult-Onset Diabetes, encompasses individuals who have Insulin 
resistance and usually have relative (rather than absolute) insulin deficiency. 
         Most individuals with Type II Diabetes exhibit intra-abdominal (visceral) 
obesity, which is closely related to the presence of Insulin resistance. In addition, 
hypertension and dyslipidemia (high triglyceride and low HDL-cholesterol levels, 
postprandial hyperlipidemia) often are present in these individuals. 
         This is the most common form of Diabetes Mellitus and is highly associated 
with a family history of Diabetes, older age, obesity and lack of exercise. It is more 
common in women, especially women with a history of Gestational Diabetes, and in 
blacks, Hispanics and Native Americans. 
GESTATIONAL DIABETES MELLITUS (GDM): 
         Gestational Diabetes Mellitus is an operational classification (rather than a 
pathophysiologic condition) identifying women who develop Diabetes Mellitus 
during gestation. Women who develop Type I Diabetes Mellitus during pregnancy 
and women with undiagnosed asymptomatic Type II Diabetes Mellitus that is 
discovered during pregnancy are classified with Gestational Diabetes Mellitus 
(GDM). In most women who develop GDM, the disorder has its onset in the third 
trimester of pregnancy. 
OTHER SPECIFIC TYPES: 
MONOGENIC DIABETES: 
         Types of Diabetes Mellitus of various known etiologies are grouped together to 
form the classification called “Other Specific Types”. This group includes persons 
with genetic defects of beta-cell function (this type of Diabetes was formerly called 
MODY or Maturity-onset Diabetes in youth) or with defects of insulin action. Persons 
with dysfunction associated with other endocrinopathies (e.g.Acromegaly), and 
persons with pancreatic dysfunction caused by drugs, chemicals or infections and they 
comprise less than 10% of DM cases 
(55)
.  
RISK FACTORS: 
         The risk factors for Type I Diabetes are still being researched. However, having 
a family member with Type I Diabetes slightly increases the risk of developing the 
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disease. Environmental factors and exposure to some viral infections have also been 
linked to the risk of developing Type I Diabetes. 
Several risk factors have been associated with Type II Diabetes and include: 
 Family history of Diabetes 
 Overweight 
 Unhealthy diet 
 Physical inactivity 
 Increasing age 
 High Blood pressure 
 Ethnicity 
 History of Gestational Diabetes 
 Poor nutrition during pregnancy 
 Impaired Glucose Tolerance (IGT) is a category of higher than normal blood 
glucose, but below the threshold for diagnosing Diabetes. 
 Changes in diet and physical activity related to rapid development and 
urbanization has led to sharp increases in the numbers of people developing 
Diabetes. 
 Pregnant women who are overweight, have been diagnosed with IGT, or have  
a family history of Diabetes are all at increased risk of developing Gestational 
Diabetes  Mellitus (GDM). In addition, having been previously diagnosed with 
Gestational Diabetes or being of certain ethnic groups puts women a increased 
risk of developing GDM 
(56)
.  
CLINICAL FEATURES: 
          Most of the symptoms are similar in both types of Diabetes but they vary in 
their degree and develop more rapidly in Type I Diabetes and more typical. Some of 
the clinical features and symptoms are listed below. 
 Glycosuria: 
When blood glucose level is above 180mg/dl, glucose appears in urine. 
It is the renal threshold for glucose. 
 Osmotic Diuresis: 
The excess glucose in renal tubules decreases re absorption of water 
result in diuresis. This leads to polyuria, polydipsia. 
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 Polyuria: 
The amount of urine may be several litres in 24 hours. This is due to 
excessive sugar in the urine which acts as a Diuretic. 
 Polydipsia, Dryness of mouth: 
Polyuria decreases water content in the body stimulates taste centre 
and in turn increases water intake. 
 Polyphagia and Predilection for sweet food: 
This symptom is due to non utilization of sugar for energy expenditure. 
 Asthenia: 
This is due to proteins depletion and increased utilization of proteins 
for energy. 
 Emaciation: 
It is due to loss of water, glycogen and triglyceride and proteins stores 
and gradually reduced muscle mass occurs. 
 Pruritis vulva , Balanitis, Genital Candidiasis, Skin Sepsis (Boils): 
This is due to irritant action of sugar on the tissue and fungal or 
bacterial infections. 
 Constipation: 
The stool becomes hard and bowel movement may take place after 
every 2 to 3 days. 
 Nausea, Headache, Blurring of Vision, 
 Mood change, Irritability, Difficulty in concentrating, Apathy, Unhealed 
wounds. 
 Frequent changes in Refractive error and Cataract (57).  
 
COMPLICATIONS: 
         People with Diabetes have an increased risk of developing a number of serious 
health problems. Consistently high blood glucose levels can lead to serious diseases 
affecting the heart and blood vessels, eyes, kidneys, nerves and teeth. In addition, 
people with Diabetes also have a higher risk of developing infections. In almost all 
high-income countries, Diabetes is a leading cause of cardiovascular disease, 
blindness, kidney failure, and lower limb amputation. Maintaining blood glucose 
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levels, blood pressure, and cholesterol at or close to normal can help delay or prevent 
Diabetes complications. Therefore people with Diabetes need regular monitoring. 
CARDIOVASCULAR DISEASE: 
        Affects the heart and blood vessels and may cause fatal complications such as 
Coronary Artery Disease (leading to heart attack) and Stroke. Cardiovascular Disease 
is the most common cause of death in people with Diabetes. High blood pressure, 
high cholesterol, high blood glucose and other risk factors contribute to increasing the 
risk of cardiovascular complications. 
DIABETIC NEPHROPATHY: 
        This is caused by damage to small blood vessels in the kidney‟s leading to 
becoming less efficient or to fail altogether. Kidney disease is much more common in 
people with Diabetes than in those without Diabetes. Maintaining near normal levels 
of blood glucose and blood pressure can greatly reduce the risk of kidney disease. 
DIABETIC NEUROPATHY: 
         Diabetes can cause damage to the nerves throughout the body when blood 
glucose and blood pressure are too high. This can lead to problems with digestion, 
erectile dysfunction, and many other functions. Among the most commonly affected 
areas are the extremities, in particular the feet. Nerve damage in these areas is called 
Peripheral Neuropathy, and can lead to pain, tingling, and loss of feeling. Loss of 
feeling is particularly important because it can allow injuries to go unnoticed, leading 
to serious infections and possible amputations. People with Diabetes carry a risk of 
amputation that may be more than 25 times greater than that of people without 
Diabetes. However, with comprehensive management, a large proportion of 
amputations related to Diabetes can be prevented. Even when amputation takes place, 
the remaining leg and the person‟s life can be saved by good follow-up care from a 
multidisciplinary foot team. People with Diabetes should regularly examine their feet. 
DIABETIC RETINOPATHY: 
         Most people with Diabetes will develop some form of Eye disease (Retinopathy) 
causing reduced vision or blindness. Consistently high levels of blood glucose, 
together with high blood pressure and high cholesterol, are the main causes of 
Retinopathy. It can be managed through regular eye checks and keeping glucose and 
lipid levels at or close to normal. 
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FOOT DAMAGE: 
         Nerve damage in the feet or poor blood flow to the feet increases the risk of 
various foot complications. Left untreated, cuts and blisters can develop serious 
infections, which often heal poorly. These infections may ultimately require toe, foot 
or leg amputation. 
SKIN CONDITIONS: 
         Diabetes may leave you more susceptible to skin problems, including bacterial 
and fungal infections. 
HEARING IMPAIRMENT: 
        Hearing problems are more common in people with Diabetes. 
ALZHEIMER'S DISEASE: 
       Type II Diabetes may increase the risk of Alzheimer's disease. The poorer your 
blood sugar control, the greater the risk appears. 
COMPLICATIONS OF GESTATIONAL DIABETES: 
       Most women who have Gestational Diabetes deliver healthy babies. However, 
Untreated or Uncontrolled blood sugar levels can cause problems for mother and 
baby. 
I. PREGNANCY COMPLICATIONS: 
 Women with any Type of Diabetes during pregnancy risk a number of 
complications if they do not carefully monitor and manage their condition. To prevent 
possible organ damage to the foetus, women with Type I Diabetes or Type II Diabetes 
should achieve target glucose levels before conception. 
II. SUBSEQUENT GESTATIONAL DIABETES: 
 Once you've Gestational Diabetes in one pregnancy, you're more likely to 
have it again with the next pregnancy 
(58)
.  
 
DIAGNOSIS: 
         Diabetes Mellitus refers to a condition in which circulating blood glucose is 
chronically elevated. In Anaemia, there are many possible causes for a high blood 
glucose. Equally, there can be wide variety of possible consequences, such that a 
physician specializing in Diabetes must have some familiarity with almost every 
system in the body. Investigation of Diabetes itself can be divided into the study of its 
causes, natural history, epidemiology, genetic basis, pathophysiological mechanism 
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and biochemical consequences, and each of its many complications requires 
investigating along similar lines. This entry provides a brief introduction to the way in 
which research findings have over the years been translated into the clinical 
investigation of Diabetes 
(59)
.  
Blood: 
1. Blood sugar estimation: 
 a. Blood sugar estimation is mandatory for confirming the diagnosis of 
Diabetes. 
 b. Both fasting and postprandial blood sugar levels are estimated. 
2. Criteria for diagnosis of Diabetes Mellitus: 
 a. Random blood sugar>200mg/dl on two occasions, 
 b. Fasting Plasma Glucose>126mg/dl and sustained elevation of plasma 
glucose concentration>200mg/dl after an oral glucose load of 75gm at 2 hours. 
3. Screening by Fasting Glucose test: 
 Fasting blood glucose determination is a screening test for Type II Diabetes 
Mellitus. It is recommended for all above age of 45 yrs and must be tested every 3 yrs 
and relatively earlier in overweight persons. A fasting plasma glucose value above 
126mg/dl is certainly indicative of Diabetes Mellitus. 
GLYCOSYLATED HAEMOGLOBIN (HbA1C): 
          Measurement of blood glucose level in Diabetics suffers from variation due to 
dietary intake of the previous day. Glycated Haemoglobin (HbA1C) provides an 
accurate and objective measure of glycaemic control over a period of weeks to 
months. In Diabetes the slow non-enzymatic covalent attachment of glucose to 
Haemoglobin (glycation) which takes place over 90-120 days that is lifespan of red 
blood cells. So it gives an estimate of Diabetic control for the preceding 3-4 months. 
There is an increase in the amount of the HbA1 relative to Non-Glycated Adult 
Haemoglobin. 
Advantages of HbA1C: 
     1. No dietary preparation or fasting is required 
     2. Increased (HbA1C) value certainly means Diabetes Mellitus, but normal value 
does not rule out IGT 
     3. It is not used to diagnose Diabetes but it gives idea about poor control and 
development of micro vascular complications. 
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Normal value: 
      Below 5.7% 
HbA1C diminished in 
1. Anaemia 
2. During pregnancy 
3. Uraemia 
4. Hemoglobinopathies 
5. Blood transfusions. 
C-PEPTIDE ASSAY: 
        C-peptide is released into circulation during conversion of pro-insulin to insulin 
which is more sensitive than insulin assay. 
OTHER INVESTIGATIONS: 
1. Lipid profile 
2. Liver function test 
3. Blood urea 
4. Serum Creatinine 
URINE: 
Glucose: 
a. Testing the urine for glucose with dipsticks is a common screening 
procedure 
b. For detecting Diabetes. 
c. Performed on urine passed 1-2 hrs after meal to maximize sensitivity. 
d. Glycosuria warrants further assessment by blood testing. 
Common cause for Glycosuria: 
             Low renal threshold which also occur in pregnancy, starvation, raised 
intracranial tension (cerebral tumors, hemorrhage and head injury) and alimentary 
glycosuria. 
Renal Glycosuria: 
             Normal renal threshold for glucose is below 180 mg/dl but glucose still 
appears in urine due to low renal threshold. It is benign condition unrelated to 
Diabetes Mellitus and runs in families, also in pregnancy. 
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Alimentary Glycosuria: 
              A rapid and transitory rise in blood glucose level after meal above the normal 
renal threshold is called lag storage curve or alimentary glycosuria and returns to 
normal after 2 hrs. 
Ketones: 
              Test for Ketone bodies is for assessing severity of Diabetes and not diagnosis 
of disease.  
              If Glycosuria and Ketonuria are present, diagnosis of diabetes is certain, 
Ketonuria also seen in fasting, strenuous exercise, diet rich in fat and low in 
carbohydrate. 
Proteins: 
             Micro albuminuria or Proteinuria in absence of urinary tract infection is an 
indicator of development of Diabetic Nephropathy and other macro vascular 
complications 
(60).
 
 
MANAGEMENT: 
             The management of Type I and II Diabetes Mellitus (DM) requires addressing 
multiple goals, with the primary goal being glycemic control. Maintaining glycemic 
control in patients with Diabetes prevents many of the micro vascular and macro 
vascular complications associated with Diabetes. This chapter presents a review of the 
prevalence, screening, diagnosis, and management of these complications. 
MICROVASCULAR: 
           Micro vascular complications of Diabetes are those long-term complications 
that affect small blood vessels. These typically include Retinopathy, Nephropathy and 
Neuropathy. 
Diabetic Retinopathy is divided into two main categories: 
 Non-proliferative Retinopathy  
 Proliferative Retinopathy. 
Non-proliferative Retinopathy is the development of Micro aneurysms, venous loops, 
Retinal Hemorrhages, hard exudates and soft exudates. 
Proliferative Retinopathy is the presence of new blood vessels, with or without 
vitreous Hemorrhage. It is a progression of Non-Proliferative Retinopathy. 
Diabetic Nephropathy is defined as persistent Proteinuria, which is characterized by   
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Progressive decline in renal function resulting in end-stage of  renal disease. 
 Diabetic Neuropathy is a heterogeneous condition associated with nerve 
pathology. The condition is classified according to the nerves affected and includes 
focal, diffuse, sensory, motor, and autonomic Neuropathy. 
MACROVASCULAR: 
          Macro vascular complications of Diabetes are primarily diseases of the 
coronary arteries, peripheral arteries, and cerebro vasculature. Early macro vascular 
disease is associated with atherosclerotic plaque in the vasculature supplying blood to 
the heart, brain, limbs, and other organs. Late stages of macro vascular disease 
involve complete obstruction of these vessels, which can increase the risks of 
Myocardial Infarction (MI), stroke, claudication and gangrene. Cardiovascular 
Disease (CVD) is the major cause of morbidity and mortality in patients with 
Diabetes. 
            The aim of treatment is to achieve normal blood glucose levels, to alleviate 
symptoms and to prevent complications. 
The four pillars of Diabetic management are, 
1. Diet 
2. Exercise 
3. Drugs –Oral hypoglycaemic agents and Insulin therapy by regular monitoring 
of  glycaemic control. 
4. Early detection and treatment of complications (61).  
1. DIET: 
          It is the cornerstone of management of Diabetes. The objective is to have good 
glycaemic control and to provide a nutritious and balanced diet. In Type II Diabetes 
the calories need to be restricted in order to avoid obesity. 
Total Caloric Intake: 
           It depends on body weight, degree of physical activity and presence of Co-
morbid illness. 
Body Mass Index (BMI): 
           It determines the total caloric requirement 
           BMI= Weight (in kg) / Height in m
2   
 
BMI Normal Range: 
    21-25 
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 The calories are derived from three principal sources like carbohydrates, proteins and 
fats. 
Carbohydrates: 
           The amount of carbohydrate recommended in the diet is upto 50-60%. Whole 
grains, ragi, wheat, millets, oats, brown rice which have low glycaemic index are 
recommended. 
Proteins: 
             Recommended amount is 12-20% of total calorie intake. Dhals or grams with 
outer skin and sprouts, lean meat, fish, egg white and chicken are preferred. 
Fat: 
             It should be 20-24% of total intake. Sunflower oil, gingely oil, safflower oil, 
olive oil rich in Mono and Polyunsaturated fats are advised. Palm oil, coconut oil and 
vanaspathi should be avoided. 
Salt: 
              Dietary salt should be less than 6g/day. 
Milk and Milk Products: 
              Contribute to 40-45% of total fat content of vegetarian diet. Skimmed milk, 
unsweetened yogurt, curd, buttermilk are recommended. 
Vegetables: 
               Fiber rich in greens, brinjal, cauliflower, gourds, grains, legumes, cereals 
and salads are advised. 
 
PHYSICAL ACTIVITY: 
            Exercise forms an important component along with drugs and diet 
management in Type II Diabetes Mellitus. Patients should be encouraged to take 
regular physical activity in form of brisk walking, jogging, swimming, gardening and 
cycling for 30 minutes daily. This improves peripheral  utilization of glucose, insulin 
sensitivity, prevents complications of Diabetes and assist in maintaining lipid profile 
and blood pressure, improves and muscle strength and beneficial for mental state of 
the individual 
(62).
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PREPARATION OF TRIAL MEDICINE 
 
Medicine Name   -  Perungaya Chooranam 
Ingredients:   
      Ferula asafetida                     - 4.2gm 
      Rock salt                                 - 8.4gm 
      Cuminum cyminum 
      Acorus calamus 
      Zingiber officinale 
      Terminalia chebu                    - 12.6gm 
      Plumbago zeylanica 
      Costus speciosus 
Procedure: 
           The above ingredients are made into fine powder separately and sieved using 
cloth. 
Dosage        :  2 gm/ Bd  
Adjuvant    :  Lukewarm water 
Duration     :  90 Days 
Text Reference:  Sarabenthira Vaithiya Rathna Vali
(63) 
                          
LITERATURE REVIEW OF TRIAL MEDICINE 
                                              PERUNGAYA CHOORANAM 
1. PERUNGAYAM 
Botanical name     -    Ferula asafoetida 
Family                   -    Apiaceae 
Nature (Suvai)      -    Kaippu, karakarappu 
Thanmai                -   Veppam 
Pirivu                     -    Kaarppu 
Parts used              -    Gum resin 
Phyto chemicals     :   ferulic acid 
umbel – liferone 
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asaresinotannols 
2- butyl propenyl disulfide 
Glucose 
Galactose 
L - arabinose 
Glucuronic acid 
Valeric acid 
(64)
  
                        Action:                          
Carminative                         
Stimulant 
Laxative 
                                                Expectorant 
             General characters:   
“தந்தவய தந்த மூ஬ததழும்஧ிணி 
                                       சருயகா஭ம் யிருச்சிங்கீடம்நா 
நந்தம்யாதம் உதாயர்த்தம் அல்குல்வ஥ாய் 
நார்ப்஧ணங்கட்ட குன்நம்ந வகாதபம்” 
-வதபன் குணயாகடம் (65
) 
 
2. SEERAGAM 
Botanical name       -  Cuminum cyminum 
Family                     -   Apiaceae 
Nature (Suvai)        -   Kaarppu, Inippu 
Thanmai                  -   Thatppam 
Pirivu                       -   Inippu 
Parts used                -   Fruit 
                  Phyto chemicals   :       
                                                            α – Pinene 
Limonene 
Linalyl acetate 
α - terpineole 
p – menthstriene 
2 – allylphenol 
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Benzaldehyde p – isopropyl 
Cuminaldehyde 
(66)
 
                         Action    :                         
Carminative     
Astringent 
Stomachic 
Astringent 
 
          General characters : 
"஧ித்ததநனும் நந்திாியனப் ஧ின்஦ப் ஧டுத்தினயன் 
சத்துருயய யுந்து஫ந்து சாதித்து  – நத்தத஦னும் 
பாசய஦யு நீதயன்று ஥ண்ய஧ப் ஧஬ப்஧டுத்தி 
வ஧ாச஦கு டாாிதசயும் வ஧ார்" 
-வதபன் வெண்பா (67) 
3. VASAMBU 
Botanical name      -   Acorus calamus 
Family                    -    Araceae 
Nature (Suvai)       -    Kaarppu 
Thanmai                 -    Veppam 
Pirivu                      -    Kaarppu 
Parts used               -    Rhizome 
               Phyto chemicals     :     
β-asarone 
sesquiterpenes    
choline  
flavones 
acoradin  
2,4,5-tri-MeObenzaldehyde 
2,5-di-MeO-benzoquinone 
Galangin 
Calameone 
acolamone 
isoacolamone 
(68)
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Action       :                Stimulant 
Stomachic                                                                                     
Anti -periodic 
Carminative 
Emetic 
              General Characters: 
“஧ாம்஧ாதி ஥ஞ்சற் புதப்புண் யலியிட஧ாகங் குன்நம் 
சூம்஧ாாி  பத்த஧ித் தம்முக ஥ாற்஫ம்யன் சூய஬சன்஦ி 
வீம்஧ாம்ய஧ காசம் பீலிகஞ் சிலி஧தம் வீ஫ிருநல் 
தாம்஧ாங் கிருநி னியயவனகு நாசிய சம்஧ிய஦ன”. 
                           -வதபன் குணயாகடம் (69) 
 
4.   CHUKKU :      
Botanical name      -    Zingiber officinale 
Family                    -    Zingiberaceae 
Nature (Suvai)       -    Kaippu, kaarppu 
Thanmai                 -    Veppam 
Pirivu                      -    Kaarppu 
Parts used               -    Underground dried stem 
               Phyto chemicals :               Gingerol 
shogaols 
dihydrogingerol 
gigerdione 
hexahydrocurcumin 
desmethyl  hexahydrocurcumin 
α-zingiberene 
β-sesquiphellandrene (70) 
                         Action    :        
Stomachic 
Carminative 
Anti Vatha    
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            General characters: 
“சூய஬ நந்தம் த஥ஞ்தசாிப்பு வதாடவநப்஧ம்நமய஬மூ஬ம் 
இயபப் ஧ிருநல் மூக்கு஥ீர் யா஬க 
வதாடநதி சாபந் ததாடர்யாத - குன்ந஥ீர்த் 
வதாடம் ஆநம்வ஧ாக்குஞ் சுக்கு" 
                   -  அகத்தினர்  குணயாகடம் 
(71)
      
5. KADUKKAI: 
Botanical name     -   Terminalia chebula  
                        Family                    -   Combretaceae 
Nature (Suvai)       -   Thuvarppu 
Thanmai                 -   Veppam 
Pirivu                      -   Inippu 
Parts used               -   Fruit 
Phyto chemicals     -   Gallic acid 
                                     Chebulagic acid 
                                      punicalagin 
                                      chebulanin 
                                      corilagin 
                                      ellagic acid 
                                      chebulinic acid 
     palmitic acid 
     oleic acid 
     linoleic acid 
     1,6-di-o-galloyl-D- glucose 
     Anthraquinones (72) 
Action   :   
                                      Stomachic 
     Digestive 
     Laxative 
     Antioxidant 
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              General characters: 
  “தாயட கழுத்தக்கி தாலு கு஫ினியிடப் 
பீயட சிலி஧தமுற் வ஧திமுடம்  – ஆயடதனட்டாத் 
தூ஬நிடி புண்யாத வசாணிகா நாய஬னிபண் 
டா஬நிடி வ஧ாம்யாிக்கா னால்” (73) 
 
6. CHITHIRA MOOLA VER PATTAI 
                        Botanical name     -   Plumbago zeylanica 
                        Family                    -    Plumbaginaceae 
                        Nature (Suvai)       -    Kaarppu, Viruviruppu 
Thanmai                 -    Veppam 
Pirivu                      -    Kaarppu 
Parts used               -    Root bark 
            Phyto chemicals     -    Plumbagin 
  Citranone 
  Elliptone 
  ß-sitosterol-glucoside 
 bakuchiol 
 phenols 
 isoaffinetin 
 saponaretin 
 flavanoids 
  psorealen 
  iso-orientin (74) 
                     Action   :                         Antiperiodic 
         Diaphoretic 
             General  characters: 
 ”கட்டியிப ணங்கிபந்தி கால்கள் அயபனாப்புக் 
கட்டிச்சூ ய஬வீக்க்க்கங் காழ்மூ஬ம்-முட்டிபத்தக் 
கட்டு஥ீ வபற்஫ங் க஦த்த த஧ருயனிறும் 
அட்டும் தகாடிவயலி னாம்”                                                                                                  
                     - அகத்தினர் குணயாகடம் 
(75)
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7. KOSHTAM 
Botanical name     -  Costus speciosus  
                        Family                    -  Costaceae 
Nature (Suvai)       -   Kaippu 
Thanmai                 -  Veppam 
Pirivu                      -  Kaarppu 
                        Parts used               -  Rhizome 
                Phyto chemicals :  
Tigogenin 
diosgenin  
a -amyrin stearate 
b-amyrin 
lupeol 
 
                           Action :                    Stomachic                                                                                                                                                                                                                                              
                                                             Stimulant                                                                                                                                
              Tonic 
      Expectorant 
      Diaphoretic (76) 
                  General characters : 
“஥ாட்டிலுறு தயட்யட ஥டுக்கம் எனுவ஥ாய்கள் 
தகாட்டதந஦ச் தசான்஦ால் குய஬யுங்காண் - கூட்டிற் 
சுபவதாடந் ததாண்யடவ஥ாய் வதா஬ாத ஧ித்தம் 
஧பவதசம் வ஧ாவந ஧஫ந்து.” 
   -அகத்தினர் குணயாகடம் 
(77)
 
8.  INDUPPU 
                        Chemical name    :      Impure Sodium chloride 
 
                          Actions                :      Stomachic 
                                                              Laxative 
                          Purgative 
                          Carminative (78)                
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       General properties: 
 “அட்டகுன்நம் நந்தம் அசிர்க்கபஞ்சூர் சீத஧ித்தத் 
    துட்டயயயும் ஥ாடிப்புண் வடாடங்கன் – தகட்டந஬க் 
கட்டுயிட யித்யதனக் காநினவ஥ாய் யங்கபப்஧ான் 
 யிட்டுயிட யிந்துப்ய஧ யின்” (79) 
 
PERUNGAYA CHOORANAM- INGREDIENTS 
 
 
              
 
                  Perungayam                                               Kadukkai 
 
 
            
Induppu  Seeragam 
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Chukku    Chithira moola ver pattai 
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                                    MATERIALS AND METHODS 
 
STUDY DESIGN 
 The clinical trial on Madhumegam (Diabetes Mellitus – Type II) was decided 
to conduct as an open label study. 
 
STUDY CENTER: 
 The entire study was conducted on patients at Out Patient Department of Govt 
Siddha Medical College, Chennai in the premises of Arignar Anna Government 
Hospital for Indian Medicine and Homeopathy, Arumbakkam, Chennai-106, during 
the period of 2016-2018. 
  
DATA COLLECTION: 
 Literary evidence from various, 
 Siddha books 
 Modern book 
 Medical journal 
 Internet 
 
POPULATION: 
 The Population consists of Diabetes accompanied by Polyuria, Polyphagia, 
Polydypsia, generalized tiredness, Fatigue, Itching all over the body and satisfying the 
inclusion and exclusion criteria mentioned below. 
 
SAMPLE SIZE: 
      40 patients. 
 
INCLUSION CRITERIA: 
 Newly identified Type II Diabetic cases only. 
 Subject within 30-60 years. 
 Blood Glucose (F) – 126mg/dl to 140 mg/dl 
 Blood Glucose (pp) - 180mg/dl to 280 mg/dl 
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 HbA1C - 6.5% to 8% 
 Polyuria 
 Polyphagia 
 Polydypsia 
 Nocturia 
 Fatigue 
 
EXCLUSION CRITERIA (BASED ON CLINICAL HISTORY): 
 H/O  Insulin Dependent Diabetes Mellitus (IDDM). 
 H/O  Cardiovascular Disease. 
 H/O  Diabetic Nephropathy. 
 H/O  Diabetic Retinopathy. 
 Pregnant women, lactating mothers, T.B affected individuals. 
 
DURATION OF TREATMENT: 
 90 days. 
      Patients were followed under the guidance and supervision of the HOD, Professor, 
Reader, Lecturer and Assistant Lecturer of Maruthuvam, PG Department, GSMC, 
Chennai-106. 
      The patients were carefully studied for their history, clinical examinations, 
investigations and management. 
 
EVALUATION OF CLINICAL PARAMETERS: 
      The history includes past, personal, family, occupation, dietary habits and 
associated history. 
 
CLINICAL INVESTIGATION: 
  Blood: 
 Blood sugar (Fasting, Post Prandial) 
 Glycaemic control: HbA1C 
 Blood urea 
 Serum creatinine 
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 Serum cholesterol  
 BMI (Body Mass Index) 
 Lipid profile 
 C – Peptide assay 
              Urine: 
 Urine Sugar (Fasting, Postprandial) 
 
SIDDHA ASSESSMENT: 
 Envagaithervugal 
 Neerkuri  
 Neikkuri 
       
A case sheet format was prepared based on the Siddha methodology like 
Envagaithervugal, Mukkutram, Nilam, Kaalam, Udalthathukkal including Neerkuri 
and Neikuri. Individual case sheet was maintained for each patient at Outpatient 
Department. 
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RESULTS AND OBSERVATION 
        The study on Madhumegam was carried out with 40 patients in the Out Patient 
Department PG Maruthuvam, Govt Siddha Medical College attached to Arignar Anna 
Govt Hospital of Indian Medicine, Chennai-106, during the period 2016-2018 were 
analyzed. The observation were made and tabulated with following criteria. 
1. Age Distribution 
2. Sex Distribution 
3. Occupational Status 
4. Socio economic Status 
5. Dietary Habits 
6. Family History 
7. Kaalam 
8. Paruva Kaalam 
9. Thinai 
10. Duration of illness 
11. Mukkutram - Vali, Azhal, Iyam 
12. Ezhu Udalthathukkal 
13. Ennvagai Thervugal 
14. Naadi 
15. Neikuri 
16. Clinical features 
17. Clinical Prognosis 
18. Urine sugar - Fasting, PostPrandial 
19. Blood Sugar - Fasting, PostPrandial 
20. HbA1C Level 
21. Grading of Results 
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1. AGE DISTRIBUTION : 
 
AGE NO. OF CASES PERCENTAGE 
30-40 9 22.5% 
41-50 13 32.5% 
51-60 18 45% 
 
 
 
Inference: 
From selected 40 cases, 9 patients (22.5%) were between 30 – 40 years, 13 
patients (32.5%) were between 41 – 50 years and 18 patients (45%) were between 51 
– 60 years old. 
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2. SEX DISTRIBUTION: 
 
 
SEX 
 
NO.OF CASES 
 
PERCENTAGE 
MALE 
 
18 
 
45% 
FEMALE 
 
22 
 
55% 
 
 
 
 
 
 
Inference: 
Out of 40 patients, 18 cases (45%) were male and 22 cases (55%) were 
female. 
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3. OCCUPATIONAL STATUS 
 
OCCUPATION NO. OF CASES PERCENTAGE 
HOUSE WIFE 16 40% 
BUSINESS 9 22.5% 
OFFICE GOING 11 27.5% 
RETIRED 4 10% 
 
 
 
 
 
Inference: 
           From selected 40 cases, 16 patients (40%) were housewives, 9 patients (22.5%) 
are doing business, 11 patients (27.5%) are office goers and 4 (10%) are retired. 
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4. SOCIO ECONOMIC STATUS: 
 
SOCIO ECONOMIC STATUS NO. OF CASES PERCENTAGE 
LOW INCOME (Below 2 lakhs) 19 47.5% 
MIDDLE INCOME (Up to 2 
lakhs) 
13 32.5% 
HIGH INCOME (More than 5 
lakhs) 
8 20% 
  
 
 
 
Inference: 
           Regarding Socio Economic Status 10 Patients (25%) were from lower income 
group, 24 patients (60%) were from Middle income group and 6 Patients (15) were 
from High income group. 
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5. DIETARY HABITS: 
 
DIETARY HABITS NO. OF CASES PERCENTAGE 
VEGETARIAN 5 12.5% 
MIXED 35 87.5% 
 
 
 
 
 
Inference: 
           Regarding Diet, out of 40 patients, 5 patients (12.5%) were taking Vegetarian 
diet and 35 patients (87.5%) were taking mixed diet. 
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   6. FAMILY HISTORY: 
 
FAMILY HISTORY 
 
NO. OF CASES 
 
PERCENTAGE 
FATHER 
 
5 
 
12.5% 
MOTHER 
 
8 
 
20% 
BOTH 
 
6 
 
15% 
NO RELEVANT HISTORY 
 
21 
 
52.5% 
 
 
 
 
Inference: 
           Regarding family history 5 patient (12.5%) fathers had diabetic, 8 patient 
(20%) mothers had diabetic, 6 patient (20%) parents both had diabetic and 21 patients 
(62.5%) had no relevant family history. 
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7. DISTRIBUTION OF KAALAM: 
 
KAALAM 
 
NO. OF CASES PERCENTAGE 
VAATHA KAALAM 
(0 – 33 ) 
2 5% 
PITHA KAALAM 
(34 – 66) 
38 95% 
KABHA KAALAM 
(67- 100) 
NIL 0% 
 
 
 
 
Inference: 
           Out of 40 patients, 2 patients (5%) were comes under Vaatha Kaalam, 38 
patients (95%) were comes under Pitha Kaalam and no patients were under Kabha 
Kaalam. 
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8. PARUVA KAALAM: 
 
PARUVA KAALAM 
( SEASONS) 
MONTH NO.OF CASES PERCENTAGE 
KAAR KAALAM Aavani, Purattasi (Mid 
Aug- Mid Oct) 
NIL 0% 
KOOTHIR KAALAM Iyppasi, Karthigai (Mid 
Oct – Mid Dec) 
NIL 0% 
MUN PANI KAALAM Margazhi, Thai (Mid 
Dec- Mid Feb) 
19 47.5% 
PIN PANI KAALAM Maasi, Panguni (Mid 
Feb – Mid Apr) 
21 52.5% 
ELAVENIL KAALAM Chithirai, Vaigasi (Mid 
Apr – Mid June) 
NIL 0% 
MUTHU VENIL 
KAALAM 
Aani,Aadi (Mid June- 
Mid Aug) 
NIL 0% 
 
 
Inference: 
           From selected 40 patients, 19 patients (47.5%) were noted in Mun Pani 
Kaalam, 21 patients (52.5%) were noted in Pin Pani Kaalam. 
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9. DISTRIBUTION OF THINAI: 
 
 
THINAI NO. OF CASES PERCENTAGE 
KURINJI 0 0% 
MULLAI 0 0% 
MARUTHAM 0 0% 
NEITHAL 40 100% 
PAALAI 0 0% 
 
 
 
 
Inference: 
            All the 40 patients were from Neithal Nilam. 
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10. DURATION OF ILLNESS:  
 
DURATION OF ILLNESS NO. OF CASES PERCENTAGE 
NEWLY IDENTIFIED 
PATIENTS 
8 20% 
3 – 6 MONTHS 32 80% 
 
 
 
 
Inference: 
           Out of 40 patients, 8 patients (20%) were comes under newly identified 
category and 32 patients (80%) were comes under to 3 – 6 months category. 
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11. REFERENCE OF MUKKUTTRAM: 
A. Affected Vali: 
CLASSIFICATION OF VALI NO. OF CASES PERCENTAGE 
PRAANAN 0 0% 
ABAANAN 40 100% 
VYAANAN 40 100% 
UDHAANAN 0 0% 
SAMAANAN 40 100% 
NAAGAN 0 0% 
KOORMAN 7 17.5% 
KIRUGARAN 40 100% 
DEVATHATHAN 40 100% 
DHANANJEYAN - - 
 
 
Inference: 
           From the selected 40 patients, all the 40 patients were affected with Abaanan, 
Vyaanan, Samaanan, Kirugaran and Devathathan. Koorman was affected in 7 patients 
(17.5%). 
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B. Affected Azhal: 
 
CLASSIFICATION OF 
AZHAL 
NO. OF CASES PERCENTAGE 
PAASAGAM (ANAL 
PITHAM) 
40 100% 
RANJAGAM 8 20% 
SADHAGAM 40 100% 
AALOSAGAM 7 17.5% 
PRASAGAM 6 15% 
 
 
 
 
Inference: 
          Out of 40 patients, all the 40 patients were affected with Paasagam and 
Saadhagam. Ranjagam was affected in 8 patients (20%), Aalosagam was affected in 7 
patients (17.5%) and Prasagam was affected in 6 patients (15%). 
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C. Affected Iyyam: 
 
CLASSIFICATION OF 
IYYAM 
NO. OF CASES PERCENTAGE 
AVALAMBAGAM 0 0% 
KILETHAGAM 40 100% 
POTHAGAM 0 0% 
THARPAGAM 0 0% 
SANTHIGAM 24 60% 
 
 
 
 
Inference: 
          Out of 40 patients, all patients were affected with Kilethagam and Santhigam 
was affected in 24 patients (60%). 
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12. EZHU UDAL THATHUKKAL: 
 
EZHU UDAL THATHUKKAL NO. OF CASES PERCENTAGE 
SAARAM 40 100% 
SENNEER 40 100% 
OON 6 15% 
KOZHUPPU 6 15% 
ENBU 24 60% 
MOOLAI 0 0% 
SUKKILAM/SURONITHAM 0 0% 
 
 
 
Inference: 
           From the above chart, we observe that Saaram and Senneer were affected in all 
the patients (100%), Oon & Kozhuppu were affected to the extent of 15% and Enbu 
was affected in 24 patients (60%).  
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13. ENN VAGAI THERVUGAL: 
 
ENN VAGAI THERVUGAL NO. OF CASES PERCENTAGE 
NAADI 40 100% 
SPARISAM 6 15% 
NAA 40 100% 
NIRAM 8 20% 
MOZHI 0 0% 
VIZHI 7 17.5% 
MALAM 8 20% 
MOOTHIRAM 40 100% 
 
 
 
Inference: 
           Regarding Enn Vagai Thervu, all the 40 patients were affected with Naadi, 
Naa, Moothiram, 8 patients (20%) were affected with Malam and Niram. Vizhi was 
affected in 7 patients (17.5%) and Sparisam was affected in 6 patients (15%). 
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14. NAADI: 
 
NAADI NO. OF CASES PERCENTAGE 
PITHA VAATHAM 28 70% 
VAATHA PITHAM 7 17.5% 
PITHA KABHAM 5 12.5% 
 
 
 
 
 
Inference: 
           Out of 40 patients, 28 patients (70%) had Pitha Vaatha naadi, 7 patients 
(17.5%) had Vaatha Pitha naadi and 5 patients (12.5%) had Pitha Kabha naadi. 
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15. NEI KURI REFERENCE: 
 
NEI KURI CHARACTER OF 
URINE 
NO. OF CASES PERCENTAGE 
VAATHA NEER SPREADS LIKE 
SNAKE 
8 20% 
PITHA NEER SPREADS LIKE 
RING 
26 65% 
KABHA NEER FLOAT LIKE PEARL 6 15% 
 
 
 
 
 
 
Inference: 
           Out of 40 patients, 8 samples (20%) show Vaatha Neer, 26 samples (65%) 
show Pitha Neer and 6 samples (15%) show Kabha Neer. 
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16. CLINICAL FEATURES: 
 
SIGNS &  SYMPTOMS NO. OF CASES PERCENTAGE 
POLYURIA 40 100% 
POLYPHAGIA 40 100% 
POLYDIPSIA 40 100% 
PRURITIS VULVAE/ BALANITIS 6 15% 
ITCHING PRESENT ALL OVER THE 
BODY 
6 15% 
 PAIN ALL OVER THE BODY  34 85% 
DRYNESS OF MOUTH & THROAT 40 100% 
CONSTIPATION 8 20% 
EMACIATION 6 15% 
SKIN INFECTION 6 15% 
 DISTURBED SLEEP  40 100% 
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Inference: 
           In respect of the patients with Madhumegam, the clinical symptoms of 
Polyuria, Polyphagia, Polydipsia, Dryness of Mouth & Throat and Disturbed sleep 
were present in all cases. Pruritis Vulvae / Balanits, Itching present all over the body, 
Skin infection and Emaciation were present in 6 cases (15%). Constipation was 
present in 8 patients (20%) and Pain present all over the body was in 34 cases (85%). 
17. CLINICAL PROGNOSIS: 
SIGNS & 
SYMPTOMS 
 
BEFORE TREATMENT 
 
AFTER TREATMENT 
 
NO. OF 
CASES 
 
PERCENTAGE 
 
NO. OF  
CASES 
 
PERCENTAGE 
POLYURIA 
 
40 
 
100% 
 
8 
 
20% 
POLYPHAGIA 
 
40 
 
100% 
 
4 
 
10% 
POLYDIPSIA 
 
40 
 
100% 
 
4 
 
10% 
PRURITIS VULVAE/ 
BALANITIS 
 
6 
 
15% 
 
0 
 
0% 
ITCHING PRESENT 
ALL OVER THE 
BODY 
 
6 
 
15% 
 
0 
 
0% 
PAIN ALL OVER 
THE BODY 
 
34 
 
85% 
 
6 
 
15% 
DRYNESS OF 
MOUTH & THROAT 
 
40 
 
100% 
 
0 
 
0% 
CONSTIPATION 
 
8 
 
20% 
 
0 
 
0% 
EMACIATION 
 
6 
 
15% 
 
3 
 
7.5% 
SKIN INFECTION 
 
6 
 
15% 
 
0 
 
0% 
DISTURBED SLEEP 
 
40 
 
100% 
 
5 
 
12.5% 
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Inference: 
   The clinical signs & symptoms were improved. After treatment, 20% 
of peoples had Polyuria, 12.5% had Polyphagia, 10% of people had Polydypsia, 15% 
had pain all over the body, 12.5% had disturbed sleep and 7.5% had emaciation. The 
symptoms of Pruritis Vulvae/ Balanitis, Itching all over the body, dryness in Mouth & 
Throat, skin infection and constipation were completely relieved. 
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18(A). BLOOD SUGAR (FASTING):  
 
BLOOD 
SUGAR 
  mg/dl 
BEFORE 
TREATMENT 
(NO. OF CASES) 
PERCENTAGE AFTER 
TREATMENT 
(NO. OF 
CASES) 
PERCENTAGE 
<120 0 0% 36 90% 
120-130 15 37.5% 4 10% 
131-140 25 62.5% 0 0% 
 
 
 
 
Inference: 
           Fasting blood sugar had controlled by 90% of cases. 
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18(B). BLOOD SUGAR (POST PRANDIAL): 
 
BLOOD 
SUGAR 
mg/dl 
BEFORE 
TREATMENT 
(NO. OF CASES) 
PERCENTAGE AFTER 
TREATMENT 
(NO.OF CASES) 
PERCENTAGE 
<179 0 0% 18 45% 
180-199 9 22.5% 15 37.5% 
>200 31 77.5% 7 17.5% 
 
 
 
Inference:  
 The Blood Sugar Post Prandial had controlled by 82.5% of cases. 
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19 (A). URINE SUGAR (FASTING): 
 
URINE 
SUGAR 
BEFORE 
TREATMENT 
(NO. OF 
CASES) 
PERCENTAGE AFTER 
TREATMENT 
(NO. OF 
CASES) 
PERCENTAGE  
(+) 8 20% 3 7.5% 
NIL 32 80% 37 92.5% 
 
 
 
 
Inference: 
           From the above chart it may be observed that urine sugar results on fasting 
after treatment had improved drastically and it was nil in 92.5% of cases after 
treatment. 
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19(B). URINE SUGAR (POST PRANDIAL): 
 
URINE 
SUGAR 
BEFORE 
TREATMENT 
(NO. OF 
CASES) 
PERCENTAGE AFTER 
TREATMENT 
(NO. OF 
CASES) 
PERCENTAGE  
(++) 8 20% 0 0% 
(+) 26 65% 5 12.5% 
NIL 6 15% 35 87.5% 
 
 
 
 
Inference: 
  It may be noted that urine sugar result on post prandial after treatment 
had improved drastically. It was nil in 87.5% of cases after treatment.  
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20. HbA1C LEVEL: 
 
HbA1C BEFORE 
TREATMENT 
(NO.OF  CASES) 
PERCENTAGE AFTER 
TREATMENT 
(NO.OF CASES) 
PERCENTAGE  
PRE-DIABETES 
5.7- 6.4 
0 0% 9 22.5% 
GOOD CONTROL 
6.5- 7.0 
13 32.5% 21 52.5% 
FAIR CONTROL 
Above 7 - 8 
27 67.5% 10 25% 
 
 
 
Inference: 
           HbA1C level had good control in 75% of cases and fair control in 20% of cases 
after treatment. 
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21(A).  BASED ON REDUCTION IN BLOOD SUGAR FASTING: 
 
 
BLOOD SUGAR  
LEVEL (F) 
 
PROGNOSIS 
 
NO. OF CASES 
 
PERCENTAGE 
30 – 40 mg/dl 
 
GOOD 
 
9 
 
22.5% 
21 – 29 mg/dl 
 
MODERATE 
 
18 
 
45% 
< 20 mg/dl 
 
MILD 
 
13 
 
32.5% 
 
 
 
 
Inference:  
 Out of 40 patients, 9 patients (22.5%) shows good result, 18 patients (45%) 
shows moderate results and 13 patients (32.5%) shows mild results. 
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21(B). BASED ON REDUCTION IN BLOOD SUGAR POST PRANDIAL: 
 
 
BLOOD SUGAR 
LEVEL (PP) 
 
PROGNOSIS 
 
NO. OF CASES 
 
PERCENTAGE 
51 - 75 mg/dl 
 
GOOD 
 
6 
 
15% 
26 - 50 mg/dl 
 
MODERATE 
 
29 
 
72.5% 
< 25 mg/dl 
 
MILD 
 
5 
 
12.5% 
 
 
 
 
Inference:  
 Out of 40 patients, 6 patients (15%) shows good result, 29 patients (72.5%) 
shows moderate results and 5 patients (12.5%) shows mild results. 
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BLOOD SUGAR LEVEL: 
 
 
S.NO 
 
 
OUT PATIENT NO. 
 BLOOD SUGAR LEVEL 
AGE/SEX BEFORE 
TREATMENT 
AFTER 
TREATMENT 
F 
(mg/dl) 
PP  
(mg/dl) 
F  
(mg/dl) 
PP  
(mg/dl) 
1 8677 48/M 127 192 106 162 
2 8693 35/F 133 186 119 141 
3 3820 60/M 139 240 126 169 
4 9305 46/M 132 214 127 180 
5 1002 48/F 134 184 106 152 
6 1126 41/M 135 245 109 205 
7 1196 52/M 140 258 130 208 
8 1208 40/M 128 244 98 192 
9 1319 44/F 133 220 111 181 
10 1543 52/F 131 200 105 166 
11 1732 46/M 126 229 95 180 
12 1811 33/M 129 242 107 196 
13 3166 37/F 128 219 100 179 
14 4732 58/F 127 208 94 177 
15 5015 52/F 134 239 112 189 
16 5177 55/M 138 257 113 221 
17 5202 54/F 129 218 100 165 
18 6323 43/M 133 230 108 195 
19 8184 48/F 140 268 122 211 
20 9328 50/M 133 222 99 181 
21 1593 57/F 127 203 114 179 
22 1786 59/F 135 275 123 242 
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23 1822 45/F 132 229 113 197 
24 3204 55/M 129 228 93 177 
25 3678 52/M 130 247 107 198 
26 7406 60/F 128 191 102 180 
27 4653 47/M 126 219 97 178 
28 4900 52/M 133 182 119 163 
29 4966 42/F 128 260 107 216 
30 5401 56/M 137 219 113 182 
31 5386 59/F 128 214 110 175 
32 6241 37/F 128 186 93 159 
33 7418 45/F 132 213 117 183 
34 7762 36/M 134 233 111 190 
35 7644 53/F 138 251 106 212 
36 8101 32/M 126 183 98 170 
37 7887 37/F 137 268 107 199 
38 7712 55/F 136 225 129 176 
39 8754 60/F 136 188 100 163 
40 9576 40/F 132 184 95 153 
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BMI CHART OF THE PATIENTS 
 
 BEFORE TREATMENT 
 
AFTER TREATMENT 
 
S.NO OP. 
NO. 
AGE 
/SEX 
WT(
kg) 
HT (cm) BMI H/L/
O 
 
WT(kg) HT (cm) BMI H/L/O 
 
1 8677 48/M 72 170 24 H 70 170 24 H 
2 8693 35/F 50 164 18 L 55 164 20 H 
3 3820 60/M 75 170 27 O 73 170 25 O 
4 9305 46/M 60 162 22 H 58 162 22 H 
5 1002 48/F 59 158 23 H 56 158 22 H 
6 1126 41/M 68 173 22 H 65 173 22 H 
7 1196 52/M 80 175 26 O 77 175 25 O 
8 1208 40/M 62 160 24 H 60 162 23 H 
9 1319 44/F 65 170 22 H 63 170 22 H 
10 1543 52/F 63 163 24 H 60 163 23 H 
11 1732 46/M 50 164 18 L 55 164 20 H 
12 1811 33/M 60 162 22 H 58 162 22 H 
13 3166 37/F 65 163 24 H 62 163 23 H 
14 4732 58/F 70 189 24 H 74 189 21 H 
15 5015 52/F 65 163 24 H 62 163 23 H 
16 5177 55/M 75 170 26 O 73 170 25 O 
17 5202 54/F 70 170 24 H 67 170 23 H 
18 6323 43/M 
 
62 
 
162 
 
23 
 
H 
 
60 
 
162 
 
23 
 
H 
19 8184 48/F 
 
68 
 
163 
 
26 
 
O 
 
66 
 
163 
 
25 
 
O 
20 9328 50/M 61 165 22 H 59 165 22 H 
21 1593 57/F 
 
62 
 
160 
 
24 
 
H 
 
60 
 
162 
 
23 
 
H 
22 1786 59/F 
 
70 
 
165 
 
26 
 
O 
 
69 
 
165 
 
25 
 
O 
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23 1822 45/F 
 
58 
 
160 
 
23 
 
H 
 
57 
 
162 
 
22 
 
H 
24 3204 55/M 50 163 18 L 54 163 20 H 
25 3678 52/M 56 157 22 H 54 157 22 H 
26 7406 60/F 
 
58 
 
160 
 
23 
 
H 
 
57 
 
162 
 
22 
 
H 
27 4653 47/M 58 163 22 H 56 163 21 H 
28 4900 52/M 50 163 18 L 55 163 21 H 
29 4966 42/F 
 
65 
 
170 
 
22 
 
H 
 
63 
 
170 
 
22 
 
H 
30 5401 56/M 61 165 21 H 59 165 22 H 
31 5386 59/F 
 
50 
 
164 
 
18 
 
L 55 164 20 H 
32 6241 37/F 
 
70 
 
170 
 
24 
 
H 
 
67 
 
170 
 
23 
 
H 
33 7418 45/F 72 170 24 H 70 170 24 H 
34 7762 36/M 
 
80 
 
175 
 
26 
 
O 74 175 24 H 
35 7644 53/F 50 163 18 L 53 163 20 H 
36 8101 32/M 
 
65 
 
170 
 
22 
 
H 
 
63 
 
170 
 
22 
 
H 
37 7887 37/F 70 165 26 O 68 165 25 O 
38 7712 55/F 
 
69 
 
165 
 
25 
 
O 
 
70 
 
165 
 
26 
 
O 
39 8754 60/F 
 
62 
 
162 
 
23 
 
H 
 
62 
 
162 
 
23 
 
H 
40 9576 40/F 62 157 25 O 59 157 24 H 
         H – HEALTHY  L – LEAN O - OVERWEIGHT 
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BIO CHEMICAL ANALYSIS OF THE PATIENTS 
 
 
S.
N
O 
 
 
 
O.P. 
NO. 
 BLOOD SUGAR LEVEL 
(mg/dl) 
URINE SUGAR LEVEL HBA1C 
(%) 
C-PEPTITE 
ASSAY 
(ng/dl)  
AGE/ 
SEX 
BT AT BT AT 
F 
 
PP F PP F PP F PP BT AT BT AT 
1 8677 48/M 127 192 106 162 NIL NIL NIL NIL 7.7 7.1 2.20 2.15 
2 8693 35/F 133 186 119 141 NIL (+) (+) NIL 8 7.2 2.89 2.90 
3 3820 60/M 139 240 126 169 (+) (+) (+) NIL 7.8 7.0 4.40 4.92 
4 9305 46/M 132 214 121 180 NIL (+) NIL NIL 7.3 6.8 2.40 2.28 
5 1002 48/F 134 184 106 152 NIL NIL NIL NIL 7.6 7.1 3.69 3.70 
6 1126 41/M 135 245 109 205 NIL (+) NIL NIL 7.4 6.3 2.65 2.50 
7 1196 52/M 140 258 130 208 (+) (++) (+) (+) 7.9 7.6 3.50 3.40 
8 1208 40/M 128 244 98 192 NIL (+) NIL NIL 6.6 6.1 2.20 1.90 
9 1319 44/F 133 220 111 181 NIL (+) NIL NIL 6.7 5.8 3.8 3.62 
10 1543 52/F 131 200 105 166 NIL NIL NIL NIL 7.1 6.5 2.80 2.68 
11 1732 46/M 126 229 95 180 NIL (+) NIL NIL 6.8 6.0 1.90 1.97 
12 1811 33/M 129 242 107 196 NIL (+) NIL NIL 6.7 6.5 2.36 2.58 
13 3166 37/F 128 219 100 179 NIL (+) NIL NIL 7.3 6.9 3.66 3.50 
14 4732 58/F 127 208 94 177 NIL (+) NIL NIL 7.0 6.5 2.44 1.19 
15 5015 52/F 134 239 112 189 NIL (+) NIL NIL 7.5 6.5 3.80 3.97 
16 5177 55/M 138 257 113 221 (+) (++) NIL (+) 8 7.4 5.18 4.71 
17 5202 54/F 129 218 100 165 NIL NIL NIL NIL 6.8 5.9 1.89 1.85 
18 6323 43/M 133 230 108 195 NIL (++) NIL NIL 6.7 6.2 3 2.93 
19 8184 48/F 140 268 122 211 (+) (++) NIL (+) 7.8 6.8 3.40 3.28 
20 9328 50/M 133 222 99 181 NIL (+) NIL NIL 7.4 7.2 3.86 3.82 
21 1593 57/F 127 203 114 179 NIL (+) NIL NIL 6.9 6.5 2.50 1.89 
22 1786 59/F 135 275 123 242 (+) (++) (+) (+) 8.0 7.9 4.88 4.70 
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23 1822 45/F 132 229 113 197 NIL (+) NIL NIL 7.1 6.8 3.22 3.38 
24 3204 55/M 129 228 93 177 NIL NIL NIL NIL 7.0 6.5 2.75 2.70 
25 3678 52/M 130 247 107 198 NIL (+) NIL NIL 7.4 6.8 3.08 3 
26 7406 60/F 128 191 102 180 NIL (+) NIL NIL 7.5 6.9 1.93 1.88 
27 4653 47/M 126 219 97 178 NIL (+) NIL NIL 7.8 6.6 3.1 3.18 
28 4900 52/M 133 182 119 163 NIL NIL NIL NIL 6.8 6.0 3.0 2.80 
29 4966 42/F 128 260 107 216 NIL (+) NIL NIL 7.9 7.2 2.10 2.0 
30 5401 56/M 137 219 113 182 NIL (+) NIL NIL 7.2 6.8 1.88 1.89 
31 5386 59/F 128 214 110 175 NIL (+) NIL NIL 6.9 6.2 2.24 2.12 
32 6241 37/F 128 186 93 159 NIL (+) NIL NIL 8 6.8 4.05 4.13 
33 7418 45/F 132 213 117 183 (+) (++) (+) NIL 6.6 5.8 3.25 3.16 
34 7762 36/M 134 233 111 190 NIL (+) NIL NIL 7.7 6.7 3.60 3.45 
35 7644 53/F 138 251 106 212 NIL (++) NIL NIL 7.5 6.6 3.26 3.46 
36 8101 32/M 126 183 98 170 NIL (+) NIL NIL 7.6 6.6 2.06 2.12 
37 7887 37/F 137 268 107 199 NIL (+) NIL NIL 7.2 6.7 1.80 1.66 
38 7712 55/F 136 225 129 176 NIL (++) NIL (+) 8.0 7.9 4.48 5.02 
39 8754 60/F 136 188 100 163 NIL (++) NIL NIL 7.8 7.2 3.32 3.38 
40 9576 40/F 132 184 95 153 NIL (+) NIL NIL 7.0 6.5 2.70 2.65 
 
BT – BEFORE TREATMENT, AT- AFTER TREATMENT, N – NIL, F- FASTING, PP – POST 
PRANDIAL 
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LABORATORY INVESTIGATION REPORT OF THE PATIENTS 
 
S.NO 
 
O.P.NO 
 
AGE/SEX 
BLOOD UREA 
(mg/dl) 
SERUM CREATININE 
(mg/dl) 
BT AT BT AT 
1 8677 48/M 28 22 0.6 0.56 
2 8693 35/F 19 24 0.5 0.62 
3 3820 60/M 26 23 0.71 0.63 
4 9305 46/M 22 16 0.54 0.60 
5 1002 48/F 16 19 0.9 0.9 
6 1126 41/M 21 22 0.65 0.52 
7 1196 52/M 38 29 0.89 0.95 
8 1208 40/M 21 23 0.88 0.81 
9 1319 44/F 27 29 0.77 0.64 
10 1543 52/F 18 16 0.93 0.86 
11 1732 46/M 42 36 0.92 0.90 
12 1811 33/M 32 28 0.68 0.70 
13 3166 37/F 20 23 0.59 0.72 
14 4732 58/F 34 35 0.81 0.83 
15 5015 52/F 16 24 0.9 0.88 
16 5177 55/M 47 40 0.86 0.81 
17 5202 54/F 26 22 0.74 0.73 
18 6323 43/M 21 20 0.65 0.66 
19 8184 48/F 28 19 0.59 0.63 
20 9328 50/M 31 33 0.98 0.96 
21 1593 57/F 28 25 0.66 0.84 
 
22 
 
1786 
 
59/F 
 
45 
 
40 
 
0.83 
 
0.81 
 
23 
 
1822 
 
45/F 
 
37 
 
29 
 
0.79 
 
0.86 
 
24 
 
3204 
 
55/M 
 
28 
 
24 
 
0.71 
 
0.66 
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25 
3678 52/M 34 31 0.77 0.74 
26 7406 60/F 18 17 0.92 0.84 
27 4653 47/M 24 24 0.69 0.63 
28 4900 52/M 33 29 0.58 0.61 
29 4966 42/F 25 26 0.60 0.68 
30 5401 56/M 37 30 0.86 0.95 
31 5386 59/F 18 22 0.94 0.67 
32 6241 37/F 35 32 0.86 0.95 
33 7418 45/F 40 38 0.68 0.54 
34 7762 36/M 32 30 0.57 0.60 
35 7644 53/F 15 18 0.90 0.83 
36 8101 32/M 26 29 0.50 0.69 
37 7887 37/F 36 31 0.81 0.74 
38 7712 55/F 21 27 0.63 0.66 
39 8754 60/F 22 18 0.70 0.82 
40 9576 40/F 35 23 0.92 0.87 
BT – BEFORE TREATMENT                                                     AT – AFTER TREATMENT 
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LIPID PROFILE: 
S. 
NO 
OP. 
NO 
BEFORE TREATMENT AFTER TREATMENT 
Total 
chol 
(mg/dl) 
Sr.Trigl 
(mg/dl) 
HDL 
(mg/
dl) 
LDL 
(mg/dl
) 
VLDL 
(mg/dl) 
Total 
chol 
(mg/dl) 
Sr.Trigl 
(mg/dl) 
HDL 
(mg/
dl) 
LDL 
(mg/dl
) 
VLDL 
(mg/dl
) 
1 8677 180 105 62.2 86 26.4 175 102 63 81 25 
2 8693 128 96 68 66 18.5 126 96.5 66.2 65.1 17.2 
3 3820 196.2 142.5 80.5 98.2 36.4 180 138.6 76 90 35.4 
4 9305 174 122 63.1 84 18.8 172 121 63 83 20.2 
5 1002 166 122 72.4 78.5 29 168 118 72 76 29.3 
6 1126 118 75 80 53.8 15.2 119 107 87 61.5 17 
7 1196 224 168 66 96 37.5 198 150 71.5 94.7 37 
8 1208 176 133 69 60 18 171 132.5 68 73.7 18.2 
9 1319 204 139 62 59 31 192 131 63.1 59 30.8 
10 1543 155 114 66 71.1 24 155.2 112 69.4 70.5 23 
11 1732 181 137 72 98 31 180 137 72.3 95 31 
12 1811 126 119 63 79 29.5 120 111 66 78.2 28 
13 3166 141 120 81 110 33 152 124.6 82 97.6 33 
14 4732 186 137 80 91 24.2 184.1 140 77 87.1 22.6 
15 5015 173 125.5 77 88.2 22.8 172 125 78 85.8 21.5 
16 5177 246 167 60.6 73 31 215 150 61 72.5 31 
17 5202 148 112 72 68.6 22 160 110 72 66.5 23 
18 6323 172 126 81.2 88 29 170 128.2 80.6 87.6 29 
19 8184 193 150 64 114 31 190 146.2 66 103 30.6 
20 9328 188 163 81 96 35.3 188.2 160 79.5 91.2 33.6 
21 1593 170 117 47.7 98.9 23.4 169 115.7 59.4 91.8 23 
22 1786 211 156 62 69.1 30 199 147 66 69.6 31.8 
23 1822 175 90 78 91 28.2 172 102 72 90.3 25.9 
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24 3204 167.4 102 66 74.2 18.8 170 113 68.2 73.5 19 
25 3678 163 121 62.5 33 41 161 123.2 66.5 80 35 
26 7406 184 143 87.6 112 36 185 140.2 83.2 97.2 35.6 
27 4653 177 123 64 91 25.4 177.5 123.2 66.5 80 35 
28 4900 151 116 72.1 53.7 27 152 114 74.8 55.2 25.2 
29 4966 169 120 37.7 107.3 24 170 121 56.6 102.3 26 
30 5401 196 120 63.3 88.6 31 176 118 63 86 31.1 
31 5386 237 139 73 89.5 28.2 200 138 70 85.1 26.5 
32 6241 166 126 71 64.4 30.5 170 131.6 77.2 64 28 
33 7418 174 136 69.4 57.5 24 174.2 135 70 59 23.3 
34 7762 171 215 52 82 43 182 195.2 54.5 80.8 40 
35 7644 174 166 68 101 33.2 180 152 69.4 98.7 32.8 
36 8101 189.3 169.1 33 122 34 189 158 49.8 105 32 
37 7887 200 144 70 66.2 32.5 197 144 71 67.5 33 
38 7712 191 155 53 92 21.8 188.2 149.2 55 91 22 
39 8754 164 128 62.7 81.8 19 174 130 66.2 83 23 
40 9576 215 172 39 121 35 200 158 50 102 34.3 
Total.Chol- Total Cholestrol, Sr. Trigl- Serum Triglycerides, HDL- High Density Lipoprotein,  
LDL- Low Density Lipoprotein, VLDL- Very Low Density Lipoprotein  
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DISCUSSION 
Diabetes Mellitus, a group of metabolic disorder in which a person has high 
blood sugar level, either because the pancreas does not produce enough Insulin, or 
because cells do not respond to the Insulin that is produced. This high blood sugar 
produces the classical symptoms of Polyuria (frequent urination), Polydipsia 
(increased thirst) and Polyphagia (increased hunger). 
           Madhumegam, is a clinical entity described by Yugimunivar in his “Yugi 
Vaidhya Chintamani 800” can be compared with Diabetes Mellitus. The classical 
symptoms are Polyuria, Polyphagia, Polydipsia, Itching all over the body and Pain all 
over the body. 
Various Siddha literature has been studied and discussed for choosing the trial 
medicine for treating Madhumegam and finally choosen “Perungaya Chooranam”, 
which was mentioned in “Sarabenthira Vaithiya Rathna Vali”. 
Authentication is a critical step for successful and reliable clinical applications 
and for further experimental studies on Siddha drugs. 
 
DRUG AUTHENTICATION: 
Authentication of given specimen is the basic starting point in developing a 
botanical product. 
A sample of specimen is collected from raw drug store and its organoleptic 
characters; Microscopic and Macroscopic examination was conducted and 
authenticated by Botanist, CCRS, Chennai. 
 
PHYSICOCHEMICAL ANALYSIS: 
 
Physicochemical parameters includes 
Loss on drying at 105
0 
C
 
 - 3.68% 
Total ash – 38.37% 
Water soluble ash – 33.88% 
Acid insoluble ash -  Less than 1% 
Water soluble extraction – 47.53% 
Alcohol soluble extraction – 13.92% 
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These values of the given sample were compared with the standard values of 
Indian pharmacopoeia. 
 
TOXICOLOGICAL STUDY: 
Acute toxicity study of the drug Perungaya Chooranam was carried out as per 
OECD guideline (Organisation For Economic Co-Operation and Developement) 
Guideline-423. The experimental protocol was approved bt The Institutional Animal 
Ethics Committee of C.L. Baid Metha College of Pharmacy, Chennai, Tamil Nadu, 
India. IAEC reference no: IAEC NO: LI/10/CLBMCP/2017. The study was 
conducted with single oral dose administration of Perungaya Chooranam. In acute 
toxicity test the Perungaya Chooranam was found to be non-toxic at the dose level of 
2000mg/kg body weight. 
SUB – ACUTE TOXICITY STUDY: 
Sub- acute toxicity study was carried out for 28 days as per OECD guidelines-
407. The animals randomly divided into control group and drug divided groups for 
low and high doses. At the end of the studies the animals were sacrificed and the 
haematological parameters, biochemical parameters, urine parameters and the 
histopathology of the vital organs like brain, liver, heart, lung and kidney were carried 
out. The study result shows that the trial medicine was safe and did not produce any 
toxic effects. 
  
PHARMACOLOGICAL EVALUATION: 
The experimental protocol was approved by The Institutional Animal Ethics 
Committee of C.L Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India. 
IAEC NO: LI/10/CLBMCP/2017. 
Pharmacological studies of the trial medicine Perungaya Chooranam showed 
ANTI-DIABETIC ACTIVITY on tested animals. 
 
BIOCHEMICAL ANALYSIS: 
Biochemical assays are needed to evaluate disease models and to drive 
biomarker analysis in translation medicine and clinical research. 
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Based on the analysis Perungaya Chooranam exhibits the properties of 
Chloride, Phosphate, Copper, Iron and Zinc. 
 
IEC:  
IEC has approved my trial medicine with the allowed sample size of 40 
patients with combined gender. 
IEC NO: GSMC-CH-ME-5/007/2016  
 
CTRI: 
The global mandate is to register all clinical trials prospectively, i.e. before the 
enrollment of the first patient. I have successfully registered my trial medicine by 
submitting the details and scientific data’s to Clinical Trial Registry. 
CTRI NO: CTRI/2018/03/012505 
 
CLINICAL STUDY: 
Clinical studies were conducted followed by CTRI registration with the 
sample size of 40 patients. 
In my study, 40 patients with Madhumegam were selected in the Department 
of Maruthuvam, Government Siddha Medical College, attached to Arignar Anna Govt 
Hospital for Indian Medicine, Arumbakkam, Chennai - 106. 
All necessary investigations were carried out to all patients and trial medicine 
was given. The results of before and after treatment of all the patients were analysed 
and discussed below. 
 
Age distribution: 
o From selected 40 cases, 9 patients (22.5%) were between 30 – 40 years, 13  
     patients (32.5%) were between 41 – 50 years and 18 patients (45%) were    
     between 51 – 60 years old. 
o Usually the non-insulin diabetes mellitus occurs only in the age group      
     above 45 years – International Diabetic Monitor. 
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 Sex distribution: 
o Out of 40 patients, 13 cases (32.5%) were male and 27 cases (67.5%) were    
female. Recent studies show that more women are prone to diabetes than  
 men. 
Occupational status: 
     o From selected 40 cases, 16 patients (40%) were housewives, 9 patients     
                (22.5%) are doing business, 11 patients (27.5%) are office goers and 4       
                (10%) are retired. 
o Nowadays due to modernisation and invention of electrical and electronic 
kitchen equipments, the women lack physical exercise and results in more 
prone to Diabetes. 
Socio-economic status 
o Regarding Socio Economic Status 19 Patients (47.5%) were from lower 
income group, 13 patients (32.5%) were from Middle income group and 8 
Patients (20%) were from High income. 
o People belonging to lower group are more prone to Madhumegam. Recent 
research indicates that the poor are more prone to diabetes. 
o Research was being conducted to analyze whether rapid changes in their 
lifestyle or the stress of poverty triggers diabetes. 
Dietary Habits: 
o Regarding Diet, out of 40 patients, 5 patients (12.5%) were taking  
     Vegetarian diet and 35  patients (87.5%) were taking mixed diet. 
o. Further it could also be noted that people who used fast and fried foods are    
     more prone to diabetes as they have more calories of fat. 
Family history: 
o Regarding family history 5 patients (12.5%) father had diabetic, 8 patients 
(20%) mother had diabetic and 6 patient (15%) parents both had diabetic 
and 21 patients (62.5%) had no relevant family history. 
o  Genetics plays an important role in Madhumegam. 
Paruvakaalam: 
o From selected 40 patients, 19 patients (47.5%) were noted in Mun Pani  
     Kaalam, 21 patients (52.5%) were noted in Pin Pani Kaalam. 
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Thinai: 
o From the selected 40 patients all (100%) were from Neithal nilam 
o Neithal nilam is more prone to Pitha diseases. 
Body built: 
o Regarding body built, 26 patients (65%) were having normal weight, 9 
     patients (22.5%) were overweight and 5 patients (12.5%) were lean. 
Duration of illness: 
o Out of 40 patients, 8 patients (20%) were under newly identified category 
and 32 patients (80%) were under 3 – 6 months category.  
 
MUKKUTRAM CLASSIFICATION: 
In Vatham: 
 
1. Abanan affected in all patients (100%) causing Polyuria, Nocturia, 
Constipation. 
2. Viyanan affected in all patients (100%) with Pain all over the body. 
3. Samanan and Kirukaran affected in all patients (100%) causing 
Polyphagia. 
4. Devethathan affected in all patients (100%) causing disturbed sleep, 
fatigue. 
5. Koorman affected in 7 patients (17.5%) causing dimness of vision. 
In Pitham: 
1. Analagam affected in all patients (100%) causing polyphagia. 
2. Sathagam affected in all patients (100%) causing lassitude. 
3. Ranjagam, Aalosagam and Prasagam affected in (20%), (17.5%), (15%) 
patients causing pallor, dimness of vision and dry skin respectively. 
In Kabham: 
1. Kilethagam affected in all patients (100%) results in Polyphagia. 
2. Santhigam affected in 24 patients (60%) causing joint pain. 
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EZHUUDALTHATHUKKAL: 
1. Saaram affected in all patients results in tiredness, general debility. 
2. Senneer affected in all cases causing pallor, dryness. 
3. Oon and Kozhuppu affected in 6 patients (15%) each causing emaciation 
4. Enbu affected in 24 patients (60%) causing joint pain. 
 
ENVAGAITHERVUGAL: 
1. Naa, Naadi and Moothiram affected in all 40 patients (100%). 
2. Malam and Niram affected in 8 patients (20%) results in constipation and 
pallor. 
3. Vizhi was affected in 7 patients (17.5%) causing dimness of vision, 
Sparisam affected in 6 patients (15%) causing dry skin. 
NAADI: 
1. 28 patients (70%) had Pitha Vatha naadi  
2. 7 patients (17.5%) had Vatha Pitha naadi  
3. 5 patients (12.5%) had Pitha Kaba naadi. 
NEIKURI: 
1. 8 samples (20%) show Vatha neer 
2. 26 samples (65%) show Pitha neer 
3. 6 samples (15%) show Kabha neer. 
 
SIGNS AND SYMPTOMS: 
1. Polyuria, Polyphagia, Polydipsia, dryness of the mouth & throat and 
disturbed sleep were present in all cases i.e 100%.  
2. Pain all over the body in 34 patients (85%). 
3. Itching and skin infection in 10 patients (25%) 
4. Constipation in 8 patients (20%). 
5. Emaciation in 4 patients (10%). 
 
CLINICAL PROGNOSIS: 
The clinical signs and symptoms were improved after treatment, 20% had 
polyurea, 10% had polyphagia, 10% of the people had polydipsia, 15% have pain all 
over the body, 7.5% had emaciation and 12.5% had disturbed sleep. Pruritis 
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vulvae/Balanitis, itching all over the body, skin infection, dryness of mouth and 
constipation were completely relieved. 
 
LABORATORY ASSESSMENT: 
Blood sugar Fasting: 
o From the selected 40 patients, before treatment 25 patients of fasting sugar  
    level were in the range of 131-140mg/dl and after treatment 36 patients  
    were <126mg/dl. 
Blood sugar Post Prandial: 
o From the selected 40 cases before treatment 31 patients of post prandial  
sugar level were > 200 mg /dl and after treatment 18 patients post prandial 
sugar level were < 179 mg/ dl. 
Urine sugar Fasting: 
o From the selected 40 patients, before treatment 8 patients showed (+) and 
32 patients showed Nil. After treatment 3 patients are reduced to (+) and 
37 patients showed Nil Urine Sugar. 
Urine sugar Post Prandial: 
o From the selected 40 patients, before treatment 26 patients showed (+) and 
8 patients showed (++). After treatment 35 patients postprandial urine 
sugar showed Nil. 
HbA1C: 
o From the selected 40 cases all patients HbA1C level is in the range of 
 6.5-8 %. After treatment 30 patients had good control range of 5.7 - 7 %. 
Investigations: 
Investigations like TC, DC, ESR, Hb, Serum cholesterol and Blood urea, were 
examined and urine analysis for albumin, sugar and deposits were also examined. 
Lipid profile, C- peptide assay were examined. 
 
SUVAI MUKKUTRAM THEORY: 
Madhumegam is primarily due to derangement of Pitha kuttram. The trial 
medicine Perungaya Chooranam predominant with Thuvarppu suvai, it neutralizes the 
deranged Pitham. 
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BIO STATISTICAL ANALYSIS: 
 The p value is highly significant (p<0.000). So, there is significant reducing of 
fasting, post prandial blood sugar level (mg) and HbA1C level among the patients for 
the treatment of Madhumegam. Hence, it is concluded that treatment was effective 
and significant.  
 
GRADING OF RESULTS: 
Out of 40 patients, 75% of cases showed good result, 15% of the cases showed 
moderate result and 10 % showed minimal significance. 
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SUMMARY 
 
 The clinical study on Madhumegam was carried out in the Post Graduate 
Department of Maruthuvam, Govt Siddha Medical College, Arignar Anna Hospital, 
Chennai-106, during the period of 2016 - 2018. 
 A total of 40 patients were treated in the Out Patient Department (OPD). The 
clinical and pathological assessment was carried out on the basis of both Siddha and 
Modern aspects. 
 All the 40 patients were treated with Perungaya Chooranam, 2g BD with 
lukewarm water for 90 days. The responses were assessed once in 7 days for all the 
patients. 
 
The peak incidence of Madhumegam was in the age group of 51- 60 yrs (45%) in  
    both sexes. 
The prevalence was higher among the lower income (47.5%). 
The disease is more common in housewives (40%). So high incidence occurs in  
   women. 
Regarding diet, the disease is seen among mixed dietary habits of about 80%. 
Regarding family history, 52.5% had no relavent history. 
Most of the patients were affected in Pitha kaalam (95%). 
In Vatham- Abaanan, Viyanan, Samanan, Kirukaran and Devathathan were affected  
   in all the cases 100%, Koorman was affected in 7 cases (17.5%). 
In Pitham-Analagam and Sathagam 100%, Ranjagam 20%, Alosagam 17.5% and   
   Prasagam 15% were affected. 
In Kabam- Kilethagam 100% and Santhigam 60% were affected. 
Among the Ezhu Udalthathukkal, Saaram, Seneer were 100% affected, Enbu 
   (60%), Oon (15%), Kozhuppu (15%) were affected. 
Regarding Envagaithervugal - Naa, Naadi and Moothiram were 100% affected    
   Niram, Malam (20%), Vizhi (17.5%), Sparisam (15%) were affected. 
Naadi – PithaVatha naadi (70%) was most commonly observed. 
,In Neikuri examination, 65% Pithaneer were observed. 
The Toxicological study of Perungaya Chooranam revealed no toxicity. 
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The pharmacological study shows Anti Diabetic Activity in Streptozotocin induced  
   diabetic rats. 
Urine sugar Fasting and Postprandial became normal in 92.5% and 87.5% of   
    patients respectively. 
Regarding Blood sugar level, fasting and post prandial blood sugar reduced in 90%  
   and 82.5% of the cases respectively. 
HbA1C level improved in 75% of cases which shows Good control in  
   Madhumegam. 
The clinical trial shows that there is significant improvement in clinical  
    manifestations of Madhumegam. 
The Biostatistical analysis of the clinical trial shows significant p-value <0.000 and   
    hence the treatment was effective and significant. 
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CONCLUSION 
 
i. Madhumegam is primarily due to derangement of Pitha kutram. 
ii. The trial medicine Perungaya Chooranam predominating with Thuvarppu 
suvai, it neutralises the deranged Pitham by Ethirurai Maruthuvam. 
iii. Perungaya Chooranam reveals no toxicity in animal models and hence proved 
to be safe in human subjects. 
iv. From Preclinical Pharmacological studies, Perungaya Chooranam has Anti-
Diabetic activity. 
v. No adverse effect was reported during the clinical study. 
vi. Perungaya Chooranam significantly reduced blood sugar level and also 
reduced clinical features of Madhumegam. 
vii. Perungaya Chooranam is cost effective. 
viii. Hence I conclude that Perungaya Chooranam will be a better Medicine that 
can be used in the treatment of Madhumegam. 
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ACUTE ORAL TOXICITY STUDY OF PERUNGAYA 
CHOORANAM (OECD GUIDELINE – 423) 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals 
of a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on 
average 2-4 steps may be necessary to allow judgment on the acute toxicity of 
the test substance.  
 This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed 
doses, adequately separated to enable a substance to be ranked for 
classification purposes and hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least 
two doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with 
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency 
and repeatability.  
 
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the 
acute toxicity of the test substance to enable its classification. The substance is 
administered orally to a group of experimental animals at one of the defined doses. 
The substance is tested using a stepwise procedure, each step using three animals of a 
single sex. Absence or presence of compound-related mortality of the animals dosed 
at one step will determine the next step, i.e. 
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− no further testing is needed. 
− dosing of three additional animals, with the same dose. 
− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance 
to one of a series of toxicity classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the Wistar albino rat, although other rodent 
species may be used. Healthy young adult animals are commonly used laboratory 
strains should be employed. Females should be nulliparous and non-pregnant. Each 
animal, at the commencement of its dosing, should be between 6 to 8 weeks old and 
the weight (150-200gm) should fall in an interval within±20 % of the mean weight of 
any previously dosed animals.  
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals 
may be group-caged by dose, but the number of animals per cage must not interfere 
with clear observations of each animal. 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and 
kept in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions 
Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained 
fromKings institute,Guindy, Chennai.All the animals were kept under standard 
environmental condition (22±3°C).  The animals had free access to water and 
standard pellet diet (Saimeera foods, Bangalore). 
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Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and 
kept in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions 
 
Preparation for Acute Toxicity Studies 
 Rats were deprived of food overnight (but not water 16-18 h) prior to administration 
of the,  PERUNGAYA CHOORANAM. 
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design. 
 
  IAEC No: LI/10/CLBMCP/2017 
Test Substance  :  PERUNGAYA CHOORNAM 
Animal Source  :  Kings institute,Guindy, Chennai. 
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 :150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number and individual   
    marking by using Picric acid. 
Numberofanimals                  : 3 Female/group,  
Routeofadministration          : Oral  
 
Diet    : Pellet feed supplied by Saimeera foods Pvt   
                                                   Ltd,Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
       provided with bedding of husk. 
Housing temperature : between 22ºC +3ºC.  
Relative humidity  : between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
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Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
Administration of Doses:  
PERUNGAYA CHOORANAM was suspended in water and administered to the 
groups of wistar albino rats in a single oral dose by gavage using a feeding needle. 
The control group received an equal volume of the vehicle. Animals were fasted 12 
hours prior to dosing. Following the period of fasting, the animals were weighed and 
then the test substance was administered. Three Female animals are used for each 
group. The dose level of 5, 50, 300and 2000 mg/kg body weight was administered 
stepwise. After the substance has been administered, food was withheld for a further 
3-4 hours. The principle of laboratory animal care was followed. Observations were 
made and recorded systematically and continuously as per the guideline after 
substance administration. The visual observations included skin changes, mobility, 
aggressively, sensitivity to sound and pain, as well as respiratory movements. Finally, 
the number of survivors was noted after 24 hrs and these animals were then monitered 
for a further 14 days and observations made daily. The toxicological effect was 
assessed on the basis of mortality. 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
Observations include changes in skin and fur, eyes and mucous membranes, 
and also respiratory, circulatory, autonomic and central nervous systems, and somato 
motor activity and behavior pattern. Attention was directed to observations of 
tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma. The principles 
and criteria summarized in the Humane Endpoints Guidance Document taken into 
consideration. Animals found in a moribund condition and animals showing severe 
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pain or enduring signs of severe distress was humanly killed. When animals are killed 
for human reasons or found dead, the time of death was recorded. 
Acute oral toxicity study of PERUNGAYA CHOORANAM 
Table 1: Dose finding experiment and its behavioral Signs of acute oral 
Toxicity 
Observation done: 
SL Group 
CONTROL 
Observation SL Group 
TEST GROUP 
Observation 
1 Body weight Normal 1 Body weight Normally increased 
 
2 Assessments of posture Normal 2 Assessments of 
posture 
Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal 3 Signs of 
Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
7 Change in skin color No significant 
color change 
7 Change in skin 
color 
No significant color 
change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 10 Sensitivity response Normal 10 Sensitivity 
response 
Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle 
gripness 
Normal 
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13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
Behaviour: 
 The animals will be observed closely for behaviour in the first four hours 
which  includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, 
catalepsy, convolusion, excitation, head twitches, lacrimation, loss of corneal reflex, 
loss of traction, piloerection  reactivity of touch, salivation, scratching, sedation, 
chewing,  head movements, sniffing, straub, tremor and writhes, diarrhea, leathery, 
sleep and coma. 
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated dose 
groups.  
Mortality: 
Animals were observed for mortality throughout the entire period. 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, 
the number of animals found dead during the test,description of toxic symptoms, 
weight changes, food and water intake 
No of animals in each group:3 
Table 2 (Observational study Results) 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
2000mg 
 
+ - - + - + - - - - - - - - - - - - - - 
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1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8.Tremors 9.Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14.Analgesia 15.Lacrimation 
16.Exophthalmos 17.Diarrhea 18. Writhing 19. Respiration 20. Mortality. (+  Present, 
-  Absent) 
 
Table 3( Body weight Observation) 
 
 
 
 
 
 
 
 
Table 3Water intake (ml/day) of Wistar albino rats group exposed to  
PERUNGAYA CHOORANAM: 
 
 
DOSE 
 
 
DAYS 
 
1 
 
6 
 
14 
CONTROL 58 ± 1.02 58±9.20 59.4±1.04 
HIGH DOSE 59.4±2.20 59.8±3.40 59.9±6.24 
P value (p)* NS NS NS 
 
 
N.S- Not Significant,**(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D 
(One-wayANOVA followed by Dunnett’s test) 
 
 
DOSE 
 
 
DAYS 
          1              7            14 
CONTROL 320.2±42.30 322.4 ± 60.10 323.6 ±52.10 
HIGH DOSE 302.4± 1.21 302 ± 2.04 304.2 ± 2.10 
P value (p)* NS NS NS 
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Table 4:Food intake (gm/day) of Wistar albino rats group exposed to  
PERUNGAYA CHOORANAM 
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 61.04±2.62 62.2±4.76 64.3±6.26 
High DOSE 69.4±4.23 70.4±6.22 71.6±4.18 
 
 
REPEATED DOSE 28-DAY ORAL TOXICITY (407) STUDY OF 
 PERUNGAYA CHOORANAM 
 
Test Substance  :  PERUNGAYA CHOORANAM 
Animal Source  : Kings institute,Guindy, Chennai 
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age     : 6-8 weeks 
Body Weight                   :150-200gm. 
Acclimatization   : Seven days prior to dose. 
Veterinary examination  : Prior and at the end of the acclimatization period. 
Identification of animals  :By cage number, animal number   and    individual  
  marking by using    Picric acid 
Diet     : Pellet feed supplied by Sai Meera Foods Pvt Ltd,   
       Bangalore 
Water     : Aqua guard portable water in polypropylene bottles. 
Housing & Environment  : The animals were housed in Polypropylene cages  
      provided with bedding of husk. 
Housing temperature  : between 22ºC±3ºC.  
Relative humidity   : between 30% and 70%, 
Air changes     : 10 to 15 per hour  
Dark and light cycle    : 12:12 hours. 
Duration of the study  : 28 Days. 
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Table 5  
 
PERUNGAYA CHOORANAM 
Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for 28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior 
to the initiation of treatment. Each animal was marked with picric acid. The females 
were nulliparous and non-pregnant. 
 
Justification for Dose Selection: 
As per OECD guideline three dose levels were selected for the study. They are low 
dose (X), mid dose (10X), high dose (20X). X is calculated by multiplying the acute 
toxicity dose (2000mg)   i.e X dose is (20mg/kg), 10X dose is (200mg/kg), 20X dose 
is (400mg/kg). 
 
Preparation and Administration of Dose: 
 PERUNGAYA CHOORANAM suspended in with water, It was administered to 
animals at the dose levels of X, 10X, 20X. The test substance suspensions were 
freshly prepared every two days once for 28 days. The control animals were 
administered vehicle only. The drug was administered orally by using oral gavage 
once daily for 28 consecutive days. 
 
 
Groups No of Rats 
Group I Vehicle control (Water) 12(6male,6 female) 
Group II  low dose X (20mg) 12 (6male,6 female) 
Group III Mid dose 10X (200mg) 12 (6male,6female) 
Group IV High dose 20X(400mg) 12(6male,6female) 
                                                                                  TOXICOLOGICAL STUDY 
 
 
 Page 
129 
 
  
Observations: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course 
of study. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the 
treated dose groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of      
study. 
Necropsy: 
All the animals were sacrificed by excessive anesthesia on day 29. Necropsy 
of all animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals 
fasted over-night. Blood samples were collected from orbital sinus using sodium 
heparin (200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for 
Hematology as anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 
minutes. 
Haematological Investigations: 
Haematological parameters were determined using Haematologyanalyzer.  
Biochemical Investigations:  
              Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
 Control and highest dose group animals will be initially subjected to histo 
pathological investigations. If any abnormality found in the highest dose group than 
the low, then the mid dose group will also be examined. Organs will be collected from 
all animals and preserved in 10% buffered neutral formalin for 24 h and washed in 
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running water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in 
an auto technicon and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten 
paraffin at 50°C and then in a cubical block of paraffin made by the “L” moulds. It 
was followed by microtome and the slides were stained with Haematoxylin-eosin red. 
 
Statistical analysis:  
Findings such as body weight changes, water and food 
consumption,hematology and blood chemistry were subjected to One-way ANOVA 
followed by dunnett test using a computer software programme – Graph pad version7. 
All data were summarized in tabular form, (Table-6 to 12) 
 
RESULTS: 
Repeated Dose 28-day oral toxic study of PERUNGAYA 
CHOORANAM 
Table 6: Body weight of Wistar albino rats group exposed to PERUNGAYA 
CHOORANAM 
 
 
 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 235.2±18.46 236.5 ± 35.10 236.6 ± 45.60 
238.7± 
56.16 
238.4 ± 66.15 
LOW DOSE 248.2 ± 65.24 250.7 ± 66.28 254.6± 55.34 256 ±56.34 256.8± 35.36 
MID DOSE 252.4± 18.34 253.3 ± 16.24 253.4± 14.12 
255.2 ± 
15.20 
256.4 ± 54.10 
HIGH DOSE 261.6± 62.24 261.4±42.22 262.4 ± 52.24 263 ± 54.28 264 ± 74.60 
P value (p)* NS NS NS NS NS 
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Table 7: Water intake (ml/day) of Wistar albino rats group exposed to  PERUNGAYA 
CHOORNAM 
 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 60.1 ± 8.72 60±1.52 60.2±1.40 61±1.32 61.4±1.62 
LOW DOSE 65.1±1.21 65.6±4.22 66.6±1.02 65.2±2.06 66.4±1.20 
MID DOSE 62.1±1.02 62.3±1.21 62.1±2.62 63.4±4.32 63.4±1.64 
HIGH 
DOSE 
64.1±1.81 64.2±1.32 64.4±1.14 64.6±1.62 65.8±2.02 
P value (p)* NS NS NS NS NS 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
 
Table 8:Food intake (gm/day) of Wistar albino rats group exposed to  
PERUNGAYA CHOORNAM 
 
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 34±4.14 34.2±6.12 34.3±2.18 34.2±1.14 34±5.62 
LOW DOSE 36.3±1.64 36.3±1.51 36.2±1.51 36.5±1.62 36.5±1.22 
MID DOSE 34.1±2.12 34.2±3.50 34.2±2.14 34.2±2.16 35.2±1.64 
HIGH DOSE 32.4±1.62 32.1±1.64 32.6±2.36 32.6±1.20 36.4±2.32 
P value (p)* NS NS NS NS NS 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’stest. 
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Table 9: Haematological parameters of Wistaralbino rats group exposed to  
PERUNGAYA CHOORNAM 
 
Category Control Low dose Mid dose High dose P value (p)* 
Haemoglobin(g/
dl) 
13.4±0.71 13.30±0.14 13.4±0.13 13.72±0.13 N.S 
Total WBC 
(×10
3   
l) 
09.41±0.22 09.32±0.22 09.34±0.22 09.30±1.10 N.S 
Neutrophils (%) 21.13±0.60 21.02±0.52 22.11±1.42 22.02±2.71 N.S 
lymphocyte (%) 82.10±1.26 82.12±1.42 83.10±2.44 83.20±2.54 N.S 
Monocyte (%) 1.1±0.03 1.1±0.01 1.2±0.04 1.1±0.03 N.S 
Eosinophil (%) 0.8±0.03 0.8±0.04 0.9±0.05 0.9±0.08 N.S 
Platelets 
cells10
3
/µl 
900.17±3.18 902.11±4.62 902.11±2.20 902.22±2.64 N.S 
Total RBC 
10
6
/µl 
9.32±0.11 9.47±0.33 9.50±0.64 9.60±0.46 N.S 
PCV% 48.10±0.2 48.62±5.30 48.8±4.70 48.4±.71 N.S 
MCHC g/dL 36.5±1.61 36.2±1.51 36.8±1.30 36.13±1.60 N.S 
MCV fL(µm
3
) 58.2±2.02 58.2±1.80 58.7±1.10 59.7±1.30 N.S 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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Table 10 :Bio chemical Parameters of Wistar albino rats group exposed to  
PERUNGAYA CHOORANAM 
BIOCHEMICAL 
PARAMETERS 
CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
GLUCOSE (R) (mg/dl) 138.10±2.02 138.12±2.10 
138.9±12.0
6 
138.12±5.25 N.S 
T.CHOLESTEROL(mg/dl) 140.14±5.10 140.15±5.20 
142.40±1.6
8 
143.21±1.10 N.S 
TRIGLY(mg/dl) 74.15±1.82 74.11±1.32 74.15±1.22 76.16±1.21 N.S 
LDL 78.6±2.13 78.7±2.05 78.10±1.03 78.40±01.32 NS 
VLDL 14.2±1.52 14.20±2.41 14.02±1.32 14.04±12.15 NS 
HDL 28.12±4.32 28.32±2.50 28.46±1.20 28.51±1.23 NS 
Ratio 
1(T.CHO/HDL) 
3.73±1.16 3.72±1.80 3.73±1.32 3.74±2.33 NS 
Ratio 2(LDL/HDL) 
 
1.92±1.22 1.92±1.20 1.93±2.20 1.94±06.02 NS 
Albumin(g/dL) 
6.21±0.22 6.22±0.52 6.4±7.20 
6.55±6.48 
NS 
  
NS- Not Significant,**(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table 11: Renal function test of of Wistar albino rats group exposed to  
PERUNGAYA CHOORANAM 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 14.50±0.29 14.50±0.29 14.46±1.18 14.42±1.22 N.S 
CREATININE 
(mg/dl) 
0.42±0.02 0.41±0.04 0.43±0.03 0.44±0.09 N.S 
BUN(mg/dL) 19.1±0.02 19.10±0.34 19.6±0.42 19.26±1.02 NS 
URIC ACID(mg/dl) 4.02±0.04 4.06±0.21 4.4±0.12 4.20±0.10 N.S 
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NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
Table 12: Liver Function Test of of Wistar albino rats group exposed to  
PERUNGAYA CHOORANAM 
 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
T BILIRUBIN(mg/dl). 0.08±0.01 0.08±0.03 0.08±0.03 0.08±0.01 N.S 
SGOT/AST(U/L) 64.11±1.53 64.12±0.22 64.24±1.54 65.74±1.53 N.S 
SGPT/ALT(U/L) 79.21±1.02 79.34±1.04 79.44±1.16 79.38±0.21 N.S 
ALP(U/L) 137.11±2.21 137±2.20 139±1.24 140.03±6.02 N.S 
T.PROTEIN(g/dL) 7.2.40±0.14 7.2±0.41 7.2±0.60 7.3±0.61 N.S 
 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test. 
 
HISTOPATHOLOGY OF VITAL ORGANS: 
 
Low dose       High dose  
 
BRAIN  
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HEART  
 
 
 
KIDNEY 
   
 
LIVER   
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LUNG 
 
 
BRAIN   
Regular marginal alignment on the neurons was observed. No signs of oedema 
or degeneration were observed.  
 
HEART  
 No evidence of pyknotic nucleus was observed. 
 
LUNG   
 No signs of airway secretion and bronchial secretion. Bronchial blood vessels 
and connective tissue appears normal with no signs of pulmonary oedema. 
 
LIVER   
 Periportal zone appears normal. No evidence of phagocytosis in intra 
cytoplasmic region were observed. 
 
KIDNEY   
 Appearance of proximal and distal convolutes tubules was normal with no 
evidence of atrophy. Lumen of distal convolutes tubule and collecting duct was 
normal. 
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AN EVALUATION OF THE SIDDHA DRUG PERUNGAYA 
CHOORANAM FOR ITS ANTI-DIABETIC ACTIVITY IN 
WISTAR ALBINO RATS 
ANIMAL PROCUREMENT AND MAINTENANCE: 
 Wistar Albino rats of either sex, weighing 150g to 200g were purchased from 
Kings Institute of Preventive Medicine Animal House, Chennai, India. Animal ethical 
guidelines of CPCSEA, Ministry of Animal Husbandry and Welfare, Govt. of India 
were strictly followed for  the care and maintenance of procured animals. The animals 
were fed on standard rodent pellet and RO water was provided ad libitum. The 
animals were kept for overnight fasting before experimentation. 
 Diabetes was induced in male Wistar Albino rats aged 2–3 months (180–200 g 
body weight) by intraperitoneal administration of STZ (single dose of 55 mg/kg b.w) 
dissolved in freshly prepared 0.01 M citrate buffer, pH 4.5. 
 After injection the animals had food and water ad libitum and were given 5% 
glucose in their drinking water for the first 24 hours to counter any initial 
hypoglycemia. The development of diabetes was confirmed after 72 hours of the 
Streptozotocin injection. After 72 hrs of STZ injection under mild anesthesia the 
blood was withdrawn from the tip of the tail of each rat and the blood glucose level 
was analyzed. Animals with more than 250 mg/dl was considered as diabetic. 
 The animals were divided into 5 groups each constituting 6 rats. Group I were 
normal rats, Group II were STZ (55 mg/kg b.w., i.p) induced diabetic rats. Group III 
STZ (55 mg/kg b.w., i.p) induced diabetic rats were treated with Glibenclamide 
5mg/kg b.w/p.o Group IV STZ (55 mg/kg b.w., i.p) induced diabetic rats were 
treated with Perungaya Chooranam 200mg/kg b.w/ p.o Group V STZ (55 mg/kg b.w., 
i.p) induced diabetic rats were treated with Perungaya Chooranam 400mg/kg b w/p.o 
for 28 days. 
 Fasting blood glucose levels was measured before the administration of 
extracts. The blood glucose levels were checked on 0th, 7th, 14th, and 21st day of the 
treatment period. Blood was collected from snipping of the rat tail. Blood glucose 
levels were measured. 
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Effect of Perungaya Chooranam in blood glucose level: 
Group  Blood glucose (mg/dl) 
Day – 0 Day – 7 Day – 14 Day – 21 Day – 28 
I 90.40±1.13 88.23±1.328 92.45±2.78 87.13±2.43 93.60±2.18 
II 
104.22±1.14 244.9±1.66 276.3±1.46 290.8±1.33 295.4±1.22 
III 103.5±1.46 152.0±1.32 142.05±1.30 116.3±1.48 104.3±1.46 
IV 99.13±1.22 221.5±1.24 191.2±2.27 161.8±1.26 128.5±1.44 
V 94.23±1.38 179.8±1.34 158.04±1.98 131.03±1.76 114.8±1.84 
 
 
 
 
 
 
 
Groups Treatment 
Group I Normal Control 
Group II Diabetic control- STZ (55 mg/kg ) 
Group III Diabetic control- Glibenclamide (5 
mg/kg) 
Group IV Diabetic control-  Perungaya Chooranam 
200mg/kg  
Group V Diabetic control-   Perungaya Chooranam 
400mg/kg  
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Effect of PERUNGAYA CHOORANAM in blood glucose level 
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CONCLUSION: 
By the observed result, the values of trial drug Perungaya chooranam treated 
with animals were compared with the positive control drug STZ 55mg/kg b.w/i.p, 
single dose. The results (mean value) are assured as a Anti- Diabetic activity of trial 
drug, 
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BIO-CHEMICAL ANALYSIS OF TRIAL MEDICINE 
 
Preparation of Sodium Carbonate extract: 
2 gm of the sample drug is mixed 5 gm of Sodium carbonate and taken in a 
100 ml beaker and 20 ml of distilled water is added. The solution is boiled for 10 
minutes, cooled and then filtered. The filtrate is called sodium carbonate extract. 
S.No EXPERIMENT OBSERVATION INFERENCE 
I                                    TEST FOR ACID RADICALS 
1a Test for Sulphate 
2 ml of the above prepared extract 
is taken in a test tube. To this 
add2ml of 4% Ammonium 
oxalate solution. 
Absence of 
White Precipitate 
Absent 
b 2ml of extract is added with 
2mlof dilute hydrochloric acid 
until the effervescence ceases off. 
Then2ml barium chloride solution 
is added. 
Absence of 
White Precipitate 
Absent 
2 Test for Chloride: 
2ml of extract is added with dilute 
nitric acid till the effervescence 
ceases. Then 2ml of silver nitrates 
solution is added. 
Presence of white 
precipitate 
obtained 
Presence of 
Chloride. 
3 Test for Phosphate 
2ml of the extract is treated with 2 
ml of Ammonium molybdate 
solution and 2ml of concentrated 
nitric acid. 
Yellow precipitate 
obtained 
Presence of 
Phosphate. 
4 Test for Carbonate: 
2ml of the extract is treated with 
2ml of magnesium sulphate 
solution. 
 
Absence of white 
precipitate 
Absent 
5 Test for Sulphide: 
1 gm of the substance is treated 
 Rotten egg smelling Absent 
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with 2ml of concentrated 
Hydrochloric acid. 
6 Test for Nitrate: 
1gm of the substance is heated 
with copper turnings and 
concentrated sulphuric acid and 
viewed the test tube 
vertically down. 
Absence of reddish 
brown gas. 
Absent 
 
7a Test for Fluoride and oxalate 
2ml of the extract is added with 
2ml of dilute acetic acid and 2ml 
of calcium chloride solution and 
heated. 
 White precipitate Absent 
b 5 drops of clear solution is added 
with 2ml of dilute sulphuric acid 
and slightly 
warmed to this, 1 ml of dilute 
potassium permanganate solution 
is added. 
 KMNO4 solution 
Decolourization 
obtained 
Absent 
8 Test for Nitrite 
3 drops of the extract is placed on 
a filter paper. On that, 2 drops a 
Acetic Acid and 2 drops of 
Benzidine solution is placed. 
Absence of 
yellowish red colour 
Absent 
9 Test for Borate 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and Alcohol (95%) 
and introduced into the blue 
flame. 
Absence of Green 
tinged flame 
Absent 
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II          TEST FOR BASIC RADICALS 
10 Test for lead 
2 ml of the extract is added with 2 
ml of Potassium iodide solution. 
Absence of Yellow 
precipitate 
Absent 
11a Test for Copper 
One pinch of substance is made 
into paste with concentrated 
Hydrochloric acid in a watch 
glass and introduced into the 
nonluminous part of the flame. 
Absence of Bluish 
green coloured 
flame. 
Absent 
b 2ml of the extract is added with 
excess of Ammonia solution. 
Presence of deep 
blue 
Presence of 
Copper. 
12 Test for Aluminium 
To the 2ml of extract. Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of White 
Precipitate. 
Absent 
13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate Solution 
is added. 
 Absence of Blood 
red colour            
Absent 
b To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate solution 
and 2 ml of concentrated HNO3 is 
added. 
Blood red colour 
obtained. 
Presence of Iron. 
14 Test for Zinc 
To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
Presence of White 
precipitate. 
Presence of Zinc. 
15 Test for Calcium 
2 ml of the extract is added with 2 
ml of 4% Ammonium Oxalate 
solution. 
Absence of White 
precipitate. 
Absent 
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16 Test for Magnesium 
2ml of extract, Sodium Hydroxide 
solution is added in drops to 
excess. 
Absence of White 
precipitate. 
Absent 
17 Test for Ammonium 
2 ml of extract few ml of 
Nessler’s Reagent and excess of 
Sodium Hydroxide solution are 
added. 
Absence of 
Reddish brown 
precipitate 
Absent 
18 Test for Potassium 
A pinch of substance is treated 
with 2 ml of Sodium Nitrite 
solution and then treated with 2 
ml of Cobal Nitrate in 30% 
glacial Acetic acid. 
Absence of Yellow 
precipitate 
 
Absent 
19 Test for Sodium 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame. 
Absence of Yellow 
colour flame 
Absent 
20 Test for Mercury 
2 ml of the extract is treated with 
2 ml of Sodium Hydroxide 
solution. 
Absence of yellow 
precipitate 
Absent 
21 Test for Arsenic 
2 ml of extract is treated with 2 
ml of silver Nitrate solution 
Absence of 
Yellow precipitate 
Absent 
22 Test for Starch. 
2ml of extract is treated with 
weak iodine solution. 
Absence of 
Blue colour 
Absent 
23 Test of reducing Sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube and 
Absence of Green 
colour  
Absent 
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allowed to boil for 2 minutes and 
added 10 drops of 
the extract and again boiled for 2 
minutes. The colour changes are 
noted. 
24 Test of the alkaloids 
2ml of the extract is treated with 
2ml of potassium Iodide solution. 
Absence of 
Red colour 
Absent 
25 Test of the proteins 
2ml of the extract is treated with 
2ml of 5% NaOH, mix well and 
add 2 drops of copper sulphate 
solution. 
Absence of 
Violet colour 
Absent 
 
 
 
RESULTS: 
The given sample (Perungaya Chooranam) contains,  
1. Chloride 
2. Phosphate 
3. Copper 
4. Iron  
5. Zinc. 
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BIO STATISTICAL ANALYSIS 
The most popular non parametric statistical tool, namely, McNemar Test analysis has 
been employed to analyses the effectiveness with the help of a hypothesis. 
FASTING BLOOD SUGAR : 
 
 
S.no 
 
Fasting blood sugar level in mg 
             Before treatment             After treatment 
1 127 106 
2 133 119 
3 139 126 
4 132 127 
5 134 106 
6 135 109 
7 140 130 
8 128 98 
9 133 111 
10 131 105 
11 126 95 
12 129 107 
13 128 100 
14 127 94 
15 134 112 
16 138 113 
17 129 100 
18 133 108 
19 140 122 
20 133 99 
21 127 114 
22 135 123 
23 132 113 
24 129 93 
25 130 107 
26 128 102 
27 126 97 
28 133 119 
29 128 107 
30 137 113 
31 128 110 
32 128 93 
33 132 117 
34 134 111 
35 138 106 
36 126 98 
37 137 107 
38 136 129 
39 136 100 
40 132 95 
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Fasting blood sugar : 
 
 ft_bt ft_at 
N 
 40 40 
   
Mean 132.0250 108.5250 
Minimum 126.00 93.00 
Maximum 140.00 130.00 
 
 
Paired Samples Statistics 
 Mean N Std. 
Deviation 
Std. Error 
Mean 
Pair 1 
ft_bt 132.0250 40 4.16633 .65876 
ft_at 108.5250 40 10.29311 1.62748 
 
 
Paired Samples Test 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
ft_bt 
- 
ft_at 
23.50000 8.30199 1.31266 20.84489 26.15511 17.903 39 0.000 
 
Ft_bt= fasting before treatment 
Ft_at=fasting after treatment 
 
Inference:   
Since the p value is highly significant (p<0.000). The hypothesis is not accepted. So  
there is significant reducing of Fasting blood sugar level (mg) among the patients for  
the treatment of Madhumegam. Hence it is concluded that the treatment was effective  
and significant. 
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Effect of Perungaya chooranam on Postprandial blood Sugar level 
in Madhumegam cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.no 
Post prandial blood sugar level in mg 
Before treatment After treatment 
1 192 162 
2 186 141 
3 240 169 
4 214 180 
5 184 152 
6 245 205 
7 258 208 
8 244 192 
9 220 181 
10 200 166 
11 229 180 
12 242 196 
13 219 179 
14 208 177 
15 239 189 
16 257 221 
17 218 165 
18 230 195 
19 268 211 
20 222 181 
21 203 179 
22 275 242 
23 229 197 
24 228 177 
25 247 198 
26 191 180 
27 219 178 
28 182 163 
29 260 216 
30 219 182 
31 214 175 
32 186 159 
33 213 183 
34 233 190 
35 251 212 
36 183 170 
37 268 199 
38 225 176 
39 188 163 
40 184 153 
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Post prandial blood sugar: 
 
 pp_bt pp_at 
N  40 40 
Minimum 182.00 141.00 
Maximum 275.00 242.00 
   
 
 
Paired Samples Statistics 
 Mean N Std. 
Deviation 
Std. Error 
Mean 
 
pp_bt 222.8250 40 26.65726 4.21488 
pp_at 183.5500 40 20.62479 3.26107 
 
 
Paired Samples Test 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
pp_bt 
- 
pp_at 
39.27500 12.77013 2.01914 35.19091 43.35909 19.451 39 0.000 
 
 
Inference:   
Since the p value is highly significant (p<0.000). The hypothesis is not accepted. So 
there is significant reducing of postprandial blood sugar level (mg) among the patients 
for the treatment of Madhumegam. Hence it is concluded that the treatment was 
effective and significant.    
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Effect of Perungaya chooranam on HbA1C level in Madhumegam cases. 
 
 
S.no 
 
HbA1C 
Before treatment After treatment 
1 7.7 7.1 
2 8 7.2 
3 7.8 7.0 
4 7.3 6.8 
5 7.6 7.1 
6 7.4 6.3 
7 7.9 7.6 
8 6.6 6.1 
9 6.7 5.8 
10 7.1 6.5 
11 6.8 6.0 
12 6.7 6.5 
13 7.3 6.9 
14 7.0 6.5 
15 7.5 6.5 
16 8 7.4 
17 6.8 5.9 
18 6.7 6.2 
19 7.8 6.8 
20 7.4 7.2 
21 6.9 6.5 
22 8.0 7.9 
23 7.1 6.8 
24 7.0 6.5 
25 7.4 6.8 
26 7.5 6.9 
27 7.8 6.6 
28 6.8 6.0 
29 7.9 7.2 
30 7.2 6.8 
31 6.9 6.2 
32 8 6.8 
33 6.6 5.8 
34 7.7 6.7 
35 7.5 6.6 
36 7.6 6.6 
37 7.2 6.7 
38 8.0 7.9 
39 7.8 7.2 
40 7.0 6.5 
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HbA1C: 
 hba_bt hba_at 
N 
 40 40 
   
Minimum 6.60 5.70 
Maximum 8.00 7.80 
 
 
Paired Samples Statistics 
 Mean N Std. 
Deviation 
Std. Error 
Mean 
 
hba_bt 7.3350 40 .45548 .07202 
hba_at 6.7700 40 .51201 .08096 
 
 
Paired Samples Test 
 Paired Differences t df Sig. 
(2-
tailed) 
Mean Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Pair 
1 
hba_bt - 
hba_at 
.56500 .29919 .04731 .46932 .66068 11.944 39 0.000 
 
 
Inference:   
Since the p value is highly significant (p<0.000). The hypothesis is not accepted. So  
there is significant reducing of HbA1C level among the patients for the treatment of  
Madhumegam. Hence it is concluded that the treatment was effective and significant. 
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   GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
     CHENNAI – 600 106 
 
CLINICAL STUDY ON “PERUNGAYA CHOORANAM” IN THE TREATMENT OF 
“MADHUMEGAM” (DIABETES MELLITUS TYPE 2) 
 
 INFORMED CONSENT FORM 
 
“I have read the foregoing information. I have had the opportunity to ask 
questions about it and any questions I have asked have been answered to my 
satisfaction. 
 
I   consent voluntarily to participate in this study and understand that I have the   right 
to withdraw from the study at any time without in any way it affecting my further 
medical care”. 
 
"I have received a copy of the information sheet/consent form". 
 
Date:  
 
Station:    
 
Signature of participant: 
 
Signature of the Guide:    Signature of theInvestigator:   
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murpdh; rpj;j kUj;Jtf; fy;Yhh;p nrd;id 106 
         mwpQh; mz;zh kUj;Jtkid nrd;id 
 
kJNkf Neha;f;fhd rpj;j kUe;jpd; (ngUq;fha #uzk;) 
ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;fhd jfty; gbtk;  
                   xg;Gjy; gbtk; 
 
Ma;thsuhy; rhd;wspf;fg;gl;lJ 
 
          ehd; ,e;j Ma;it Fwpj;j midj;J tpguq;fisAk; 
Nehahspf;F GhpAk; tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd; 
 
Njjp : ifnahg;gk; : 
,lk; :  ngah; : 
 
Nehahspapd; xg;Gjy; 
     vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk;, kUe;jpd; jd;ik 
kw;Wk; kUj;Jt topKiw gw;wpAk;, njhlh;e;J vdJ cly; ,af;fj;ij  
fz;fhzpf;fTk; ,mjid ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l 
ghpNrhjidfs; gw;wp jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy;    
tpsf;fpf; $wg;gl;lJ. 
 ehd; kUj;Jt Ma;tpd; NghJ ,fhuzk; vJTk; $whky; ,vg;nghOJ 
Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;J nfhs;Sk; 
chpikia njhpe;jpUf;fpd;Nwd.; ehd; vd;Dila Rje;jpukhf Njh;T 
nra;Ak; chpikiaf; nfhz;L kJNkf  Neha;f;fhd ngUq;fha #uzk; 
kUe;jpd; gufupg;Gj; jpwidf; fz;lwpak; kUj;Jt Ma;tpw;F vd;id 
cl;gLj;j xg;Gjy; mspf;fpNwd;.  
 
Njjp :                                    ifnahg;gk; : 
,lk; :                                       ngah; :  
cwTKiw:rhl;rpf;fhuh; ifnahg;gk; ngah;:  
Njjp :  
,lk; : 
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CASE SHEET PROFORMA 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
POST GRADUATE DEPARTMENT – MARUTHUVAM BRANCH 
CHENNAI – 600 106. 
 
CASE SHEET PROFORMA FOR MADHUMEGAM 
(NON INSULIN DEPENDENT DIABETES MELLITUS – NIDDM) 
 
OP No / IP No  :    Nationality : Indian 
 
Ward No  :    Religion :  
 
Bed No   :    D.O.A  : 
 
Name  
(In Block Letters) :    D.O.D  : 
 
Age   :    No of Days 
       Treated  : 
Sex   : Male/ Female    
 
Occupation  :    Diagnosis : 
 
Income  :  /Month Result  : 
 
Permanent Address : 
 
 
 
 
Temporary Address : Govt. Siddha Medical College, 
  Chennai – 600 106. 
 
 
1. Complaint and duration  : 
 
 
 
2. History of present illness  : 
 
 
 
3. History of previous illness  : 
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4. Personal history 
 Marital History  : 
 Occupation   : 
 Environment   : 
 Social History   : 
 Habits    : 
5. Family history   
SIDDHA ASPECT 
GENERAL CONDITION ON ADMISSION 
1. NILAM: 5 
 Kurinji 
 Mullai 
 Marutham 
 Neithal 
 Paalai 
2. PARUVA KAALAM: 6 
 Kaar Kaalam   : (Aavani, Purattasi) 
 Koothir Kaalam : (Ayppasi, Karthigai) 
 Munpani Kaalam : (Maarkazhi, Thai) 
 Pinpani Kaalam : (Maasi, Panguni) 
 Elavenil Kaalam : (Chittirai, Vaikasi) 
 Mudhuvenil Kaalam : (Aani, Aadi)  
3. UDAL: 4 
  Vali Udal 
  Azhal Udal 
  Iya Udal 
  Kalappu Udal 
4. KANMENTHIRIYANGAL: 5 
  Vaai 
  Kaal 
  Kai 
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  Eruvai 
  Karuvai 
 
5. PORI / PULANGAL: 5 
 Mei - Ooru 
Vaai - Suvai 
Kann - Oli 
Mookku - Nattram 
Sevi - Osai 
6. GUNAM: 3 
 Sathuva Gunam 
 Rajo Gunam  
 Thamo Gunam 
7. UDAL KATTUGAL: 7 
 Saaram 
 Senneer 
 Oon 
 Kozhuppu 
 Enbu 
 Moolai 
 Sukkilam / Suronitham 
8. MALAM: 3 
  Malam 
 Moothiram 
 Viyarvai 
9. MUKKUTRANGAL 
         VALI 
   Piraanan 
   Abaanan 
   Uthaanan 
   Viyaanan 
   Samaanan 
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           AZHAL 
   Anala Pitham 
   Ranjaga Pitham 
   Aalosaga Pitham 
 Praasaga Pitham 
   Saathaga Pitham 
  IYAM 
   Avalambakam 
   Kilethagam 
   Pothagam 
   Tharpagam 
   Santhigam 
 
10. ENVAGAI THERVU 
   Naadi: 
  Sparisam: 
  Naa: 
  Niram: 
  Mozhi: 
  Vizhi:  
  Malam: 
Niram 
   Irugal 
   Ilagal 
   Moothiram: 
  Neerkuri: 
Niram 
Edai 
Manam 
Nurai 
Enjal 
Neikuri: 
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MODERN METHODS: 
GENERAL EXAMINATION: 
Consciousness and Intelligence 
Voice and Speech 
General appearance 
Height and Weight 
Anaemia 
Cyanosis 
JVP 
Jaundice 
Clubbing 
Ascites 
       Oedema 
      Lymphadenopathy 
     Temperature 
     Respiration 
     Pulse 
     Blood Pressure 
INVESTIGATION 
A)BLOOD INVESTIGATIONS: 
 
BLOOD INVESTIGATIONS 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT 
Hb  (gms/dl)   
T.RBC (millions cells/cu.mm)   
 
ESR (mm) 
½ hr   
1 hr   
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T.WBC (cells/cu.mm)   
Differential  
Count (%) 
Polymorphs   
Lymphocytes   
Monocytes   
Eosinophils   
Basophils   
 
 
BLOOD INVESTIGATIONS 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT 
Blood 
glucose  
(mg/dl) 
F   
PP   
R   
Renal 
Function 
Test 
Blood Urea   
Serum 
creatinine 
  
 
B) URINE INVESTIGATIONS: 
 
 
URINE INVESTIGATIONS 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT 
Albumin   
Sugar   
Deposits   
Ketone Bodies   
 
C) SPECIFIC INVESTIGATIONS: 
HbA1C: 
C- peptide assay: 
 
D) BODYMASS INDEX (BMI) 
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SIGN AND SYMPTOMS: 
 
S.N
o 
 
CLINICAL 
FEATURE
S 
 
BEFORE 
TREATME
NT 
 
DURATION TREATMENT 
 
AFTER 
TREATME
NT 
14
t
h 
Da
y 
21
s
t
 
Da
y 
28
t
h
 
Da
y 
35
t
h
 
Da
y 
42
n
d
 
Da
y 
49
t
h
 
Da
y 
1 POLYURIA         
2 POLYPHAGA         
3 POLYDIPSIA         
4 PRURITIS 
VULVA 
        
5 ITCHING 
ALL OVER 
THE BODY 
        
6 DRYNESS OF 
THE MOUTH      
AND 
THROAT 
        
7 CONSTIPATI
ON 
        
8 DISTURBED 
SLEEP 
        
9 PAIN ALL 
OVER THE 
BODY 
        
10 SKIN 
INFECTION 
        
11 EMACIATIO
N 
        
12 ABDOMINAL 
PAIN 
        
13 IMPOTENCE         
14 GLYCOSURA         
 
Others specify, if any 
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DIAGNOSIS 
MADHUMEGAM  (TYPE II DIABETES MELLITUS) 
TRIAL MEDICINE:     PERUNGAYA CHOORANAM 
 DOSE :    2 Gram/ bd 
Anubanam:     LUKE WARM WATER 
 Duration of Treatment: 90 days  
 
DAILY REPORT 
 
MEDICINE 
  
 
ADVICE: 
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